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ABSTRACT 
 
 Vitronectin is a human circulatory protein that is recruited to the extracellular matrix 
(ECM) during tissue remodeling pathways linked to injury, inflammation, and tumor 
metastasis.  Whereas circulating vitronectin is monomeric, the tissue-associated form is 
multimeric and contains multivalent binding sites for both cell-surface receptors and 
components of the extracellular matrix.  In addition, matrix-associated vitronectin 
directly regulates plasmin-regulated matrix proteolysis through the localization and 
stabilization of the serine protease inhibitor, plasminogen activator inhibitor type-1 (PAI-
1).  As a component of the ECM, vitronectin adopts a pro-adhesive role, providing a 
unique regulatory link between cell adhesion and pericellular proteolysis.  The 
mechanism by which vitronectin interconverts between a monomeric, circulating protein 
and a multimeric ECM component remains to be established.  Vitronectin shows a high 
degree of conformational flexibility, and in vitro studies demonstrate that a number of 
chaotropic agents and macromolecular ligands like PAI-1 are able to induce the 
multimerization of vitronectin into higher-order forms.  The induced multimeric form of 
vitronectin shows similar ligand-binding properties to that of the matrix-associated form, 
with a potential for multivalent interactions with biological partners including cell-
surface receptors and ECM components.  The following dissertation serves to summarize 
a graduate research project designed to address the working hypothesis that PAI-1 
represents a physiological cofactor for the conversion of vitronectin from a circulating, 
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monomeric form to a matrix-associated, “activated” form.  PAI-1-binding to 
vitronectin induces the formation of higher-order complexes that display altered 
adhesive properties distinct from the circulating (monomeric) form of vitronectin.  
These altered adhesive properties arise from the formation of multivalent binding sites 
for both cell surfaces and components of the ECM.  Formation of vitronectin/PAI-1 
complexes follows a step-wise assembly process that is dependent on protein 
concentration and time, ultimately leading to an increased accumulation of vitronectin 
at the cell-matrix interface.  To address this hypothesis, biophysical studies were 
designed to evaluate the mechanism of assembly of PAI-1/vitronectin complexes and the 
pathway leading to multimerization of vitronectin.  These studies were performed in 
parallel with cell- and matrix-binding experiments to establish a correlation between PAI-
1-induced multimerization with enhanced adhesive properties and and conversion of 
vitronectin into a matrix-associated form.      
 
 
 
 
 
 
 
 
 
 iv
 
TABLE OF CONTENTS 
Chapter                                                                                                    Page 
1. BACKGROUND INFORMATION AND INTRODUCTION 
 TO RESEARCH AIMS ......................................................................................1 
 Introduction and Project Overview ..................................................................1 
 Discovery of Vitronectin as an Adhesive Component of Blood ......................3 
 Structural Organization and Ligand-Binding Sites of Vitronectin................3 
  The Somatomedin B domain........................................................................4 
  The Connecting Segment..............................................................................8 
  The Central Domain ...................................................................................10 
  The C-Terminal Domain ............................................................................11 
 Biological Functions of Vitronectin.................................................................12 
  Vitronectin is an Adhesive Component of the Pericellular  
  Environment................................................................................................12 
  Vitronectin Regulates Thrombosis and Fibrinolysis ...............................16 
  Vitronectin Regulates the Immune Response of Complement ...............18 
  Vitronectin and Embryonic Development ................................................19 
  Vitronectin in Wound Healing and Disease..............................................20 
 Distribution of Vitronectin in Circulation and Tissues .................................21  
  Statement of a Scientific Problem .............................................................25  
 Conformational Flexibility of Vitronectin – Testing the  
 Mechanisms of Activation ................................................................................25 
  Working Hypothesis ...................................................................................28 
  Research Aims.............................................................................................28 
   Aim 1:  To test the effects of PAI-1-induced multimerization 
   on the interaction of vitronectin with cell-surface integrins and  
   components of the ECM .......................................................................30 
   Aim 2:  To evaluate the effects of PAI-1-induced multimerization 
   of vitronectin in a living cell system using human fibroblasts ..........30 
   Aim 3:  To study the mechanism of assembly of higher-order  
   vitronectin/PAI-1 complexes ................................................................31 
 
2. PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 PROMOTES  
 THE SELF-ASSOCIATION OF VITRONECTIN INTO COMPLEXES 
 EXHIBITING ALTERED INCORPORATION INTO THE 
 EXTRACELLULAR MATRIX.......................................................................33 
  Introduction.................................................................................................33 
  Materials and Methods...............................................................................35 
   Proteins and Antibodies .......................................................................35 
 v
   Size Exlusion HPLC..............................................................................35 
   SDS-PAGE and Western Blotting .......................................................36 
   Fluorescence Measurements ................................................................37 
   Cell Binding Assays ..............................................................................38 
   Matrix Binding Assays .........................................................................38 
   Integrin Binding Assays .......................................................................39 
  Results ..........................................................................................................39 
   Size Exlusion HPLC Was Used to Monitor the Formation of 
   Large Complexes Resulting from PAI-1 Binding to Vitronectin .....39 
   PAI-1 Effects on Vitronectin Enhance Its Interaction with 
   Extracellular Matrices..........................................................................43 
   The Time Course of PAI-1-Induced Multimerization of 
   Vitronectin Parallels Enhanced Association with the ECM .............45 
   Enhancement of Binding of Vitronectin/PAI-1 Complexes to 
   ECM is Dependent on Ionic Strength .................................................49 
   Multimerization Promoted by PAI-1 Binding Enhances the  
   Interaction of Vitronectin with Cell Surface Receptors....................53 
  Discussion.....................................................................................................58 
 
3. PLASMINOGEN ACTIVATOR INHIBITOR-1 PROMOTES THE 
 RELOCALIZATION OF VITRONECTIN TO THE  
 EXTRACELLULAR MATRIX.......................................................................65 
  Introduction.................................................................................................65 
  Materials and Methods...............................................................................67 
   Proteins and Antibodies .......................................................................67 
   Cell Culture ...........................................................................................67 
   Iodination of Vitronectin......................................................................68 
   Binding and Degradation of Vitronectin ............................................68 
   Immunofluorescence Microscopy........................................................69 
   Isolation of ECM from Fibroblast Monolayers..................................70 
  Results ..........................................................................................................71 
   PAI-1 Binding Promotes Increased Processing of Vitronectin 
   By Human A1-F Fibroblasts ................................................................71 
   PAI-1 Promotes Increased Binding of Vitronectin to Human  
   Fibroblast Monolayers..........................................................................73 
   Binding of Vitronectin/PAI-1 Complexes to Fibroblast 
   Monolayers is Dependent on the Presence of Active PAI-1 ..............76 
   Immunofluorescent Localization of Vitronectin and PAI-1 
   Demonstrates the Effects of Complex Formation on  
   Fibroblast Association and Degradation ............................................79 
   Turnover of PAI-1/Vitronectin Complexes by A1-F 
   Fibroblasts is Partially Integrin-Dependent.......................................85 
   Enhancement of Vitronectin Binding to Fibroblast Monolayers 
   is Dependent on the Native Structure of PAI-1..................................87 
 vi
  Discussion.....................................................................................................88 
 
4. A MECHANISM FOR ASSEMBLY OF COMPLEXES OF 
 VITRONECTIN AND PAI-1 FROM SEDIMENTATION 
 VELOCITY ANALYSIS..................................................................................92 
  Introduction.................................................................................................92 
  Materials and Methods...............................................................................95 
   Purification and Fluorescent Labeling of Vitronectin.......................95 
   Mutagenesis, Expression and Purification of Recombinant 
   PAI-1 ......................................................................................................96 
   Sedimentation Velocity Experiments ..................................................97 
   Hydrodynamic Modeling of Sedimentation Velocity Data ...............97 
   Multi-Signal Analysis of Sedimentation Data for Fluorescently- 
   Labeled PAI-1/Vitronectin Mixtures ..................................................99 
  Results ........................................................................................................100 
   Characterization of PAI-1 and Vitronectin......................................100 
   Mixtures of PAI-1 and Vitronectin Form Reversible Higher- 
   Order Complexes ................................................................................102 
   Formation of Higher-Order Complexes Occurs in a  
   Concentration-Dependent Fashion....................................................109 
   Multi-Signal Sedimentation Velocity Analysis Confirms the 
   Binding of Two PAI-1 Molecules to Vitronectin..............................112 
   Oligomeric Forms of Vitronectin Persist at Long Incubation 
   Times ....................................................................................................119 
   Salt Effects Demonstrate the Potential Role of Ionic Interactions 
   In the Formation of a Vitronectin/PAI-1 Complex..........................120 
   Assembly of PAI-1/Vitronectin Complexes is Independent 
   of the Anti-Protease Activity of the Inhibitor...................................123 
  Discussion...................................................................................................127 
 
  Bibliography/List of References ..............................................................132 
 
  Vitae ...........................................................................................................147 
 
 
 
 
 
 
 
 
 
 
 
 vii
LIST OF TABLES 
Table                                                                                                      Page 
1-I Deposition of vitronectin in injured/diseased tissue ......................................23 
 
4-I Sedimentation coefficients for PAI-1, vitronectin and PAI-1/ 
 vitronectin complexes .....................................................................................103 
4-II Assembly of PAI-1 and vitronectin into intermediate and higher- 
 order complexes ..............................................................................................107 
4-III Assembly of complexes between different recombinant forms of 
 PAI-1 and vitronectin .....................................................................................125 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 viii
LIST OF FIGURES 
Figure                                                                                                    Page 
1-1 Domain organization of vitronectin ..................................................................5  
1-2 Vitronectin is linked to many biological functions ........................................13   
1-3 Comparison of active and latent forms of PAI-1 ...........................................17 
1-4 Models for evaluating the structural/functional activation of  
 vitronectin..........................................................................................................27  
1-5 Schematic representing the working model to be investigated.....................29 
 
2-1 Size-exclusion HPLC evaluation of PAI-1-induced multimerization of 
vitronectin..........................................................................................................41 
2-2 PAI-1 is detected in high molecular weight vitronectin complexes..............42 
2-3 Complexes of vitronectin and PAI-1 associate with the ECM......................44 
2-4 Vitronectin deposition into the ECM is dependent on PAI-1 binding .........46 
2-5 Evaluation of the effects of multimerization of vitronectin on  
 binding to the ECM using tPA to neurtralize PAI-1 .....................................48 
2-6 Effects of increase ionic strength on PAI-1-mediated binding of 
 vitronectin to ECM ...........................................................................................50 
2-7 Fluorescence experiments using NBD-labeled PAI-1 demostrate that  
 PAI-1 binding to vitronectin is not influenced by ionic strength ................52 
2-8 PAI-1 enhances the binding of radiolabeled vitronectin to smooth 
 muscle cells ........................................................................................................54 
2-9 PAI-1-induced multimerization enhances the binding of vitronectin 
 to GPIIbIIIa.......................................................................................................56 
2-10 Effects of EDTA, ionic strength, and addition of tPA on PAI-1- 
 mediated binding of vitronectin to GPIIbIIIa................................................57 
2-11 A model for association of vitronectin into complexes with altered 
 adhesive properties ...........................................................................................62 
 
3-1 SDS-PAGE analysis of iodinated-vitronectin.................................................72 
3-2 Vitronectin degradation by human fibroblasts is dependent on  
 PAI-1 binding ....................................................................................................74 
3-3 PAI-1 binding enhances the association of vitronectin with  
 fibroblast monolayers .......................................................................................75 
3-4 Effect if chlorate treatment on vitronectin binding to fibroblast 
 monolayers in the presence and absence of added PAI-1 .............................77 
3-5 Effect of tPA-mediated release of active PAI-1 on vitronectin 
 binding to fibroblast monolayers.....................................................................78 
3-6 Effects of PAI-1-induced formation of higher-order complexes on the 
 cellular localization of vitronectin on human fibroblasts..............................80 
 ix
3-7 Immunofluorescent localization of vitronectin demonstrates enhanced 
binding of higher-order PAI-1/vitronectin mulitmers to ECM....................83 
3-8 Fluorescent microscopy demonstrates the co-localization of  
 vitronectin and PAI-1 on human fibroblasts..................................................84 
3-9 Cell turnover and binding experiments demonstrate the role of integrins 
 And native PAI-1 in the turnover of vitronectin by fibroblasts ...................86 
 
4-1 Sedimentation velocity analysis of PAI-1 and vitronectin 
 using SEDFIT..................................................................................................101 
4-2 Sedimentation velocity analysis of an equimolar PAI-1/vitronectin 
 mixture using SEDFIT ...................................................................................105 
4-3 c(s) distribution analysis of equimolar mixtures of PAI-1 and 
 vitronectin........................................................................................................106 
4-4 SV analysis to evaluate the concentration dependence of formation of 
 higher-order PAI-1/vitronectin complexes ...................................................110 
4-5 Multisignal analysis of complex formation between fluorescently- 
 labeled vitronectin and PAI-1 using SEDFIT ..............................................114 
4-6 Global multisignal analysis of a PAI-1/vitronectin mixture using 
SEDPHAT........................................................................................................116 
4-7 Multisignal analysis demonstrates the formation of a 2:1 PAI-1/ 
 vitronectin complex at 6.5 S ...........................................................................118 
4-8 Test for the formation of vitronectin oligomers as a function of time .......121 
4-9 Test for the effects of NaCl concentration on the formation of  
 PAI-1/vitronectin complexes ..........................................................................122 
4-10 c(s) distribution analysis of equimolar mixtures of mutant forms of 
 PAI-1 and human vitronectin ........................................................................124 
4-11 Model for formation of multivalent complexes via the 6.5 S  
 PAI-1/vitronectin intermediate......................................................................130 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 x
LIST OF SYMBOLS AND ABBREVIATIONS 
AT-IIa Antithrombin-thrombin complex 
BSA Bovine serum albumin 
DMEM Dulbecco’s Modified Eagle Medium 
ECM Extracellular matrix 
ELISA Enzyme-linked immunosorbent assay 
FBS Fetal bovine serum 
FITC Fluoroscein isothiocyanate 
GAG(s) Glycosaminoglycan(s) 
HPLC High pressure liquid chromatography 
PAGE Polyacrylamide gel electrophoresis 
PAI-1 Plasminogen activator inhibitor type-1 
PBS Phosphate buffered saline 
RGD Arginine-glycine-aspartate integrin binding locus 
RGDS Arginine-glycine-aspartate-serine tetrapeptide 
SMB Somatomedin B domain 
TCA Trichloroacetic acid 
tPA Tissue-type plasminogen activator 
uPA Urokinase-type plasminogen activator 
uPAR Urokinase receptor 
VN Vitronectin 
µM Micromolar 
RCL Reactive center loop 
Serpin Serine protease inhibitor 
SV Sedimentation velocity 
SDS Sodium dodecyl sulfate 
RMSD Root mean square deviation 
 
 
 
 
 CHAPTER 1 
 
BACKGROUND INFORMATION AND INTRODUCTION  
TO RESEARCH AIMS  
 
 
Introduction and Project Overview 
 The extracellular matrix (ECM) is an intricate system of proteins and polysaccharides 
that serves as a scaffold for cellular activities such as attachment, migration, and invasion 
[1,2].  Molecules that make up the ECM include integral components such as collagens, 
laminins, and proteoglycans, as well as plasma-derived proteins that upon certain 
biological stimuli become deposited into the tissue matrix [1-3].  The various components 
of the ECM play active and complex roles in regulating the behavior of attached cells, 
directly controlling cell shape, proliferation, differentiation, morphogenesis, movement, 
and survival [2].  In pathological states, such as tissue wounding, inflammation, and 
tumor metastasis, the normal composition and functioning of the ECM can be profoundly 
perturbed in ways that can significantly affect the behaviors of surrounding cells [1-3].  
Perturbations in the ECM occur through pathways of tissue remodeling that are carried 
out by the combined efforts of proteolytic enzyme systems and multi-functional adhesive 
proteins [2-5].   
 Tissue remodeling refers to transient or permanent alterations in the molecular 
architecture of the ECM and occurs in a variety of physiological and pathological 
processes, including ovulation, spermatogenesis, wound healing, inflammation, and 
cancer [4].  Such alterations occur through processes that involve both breakdown and 
1
 assembly of ECM components, resulting in significant changes in the structural 
composition of the ECM and the behavioral signals that it presents to nearby cells [2-5].  
In a recent review by Davis et al. [2], various mechanisms of tissue remodeling are 
discussed that lead to the exposure of “matricryptic” cell/matrix-recognition sites, which 
are not available in the mature, secreted forms of molecules making up the ECM.  These 
exposed matricryptic sites provide new, local signals that directly regulate cellular and 
tissue responses to events like injury, inflammation, and cancer [2].   
 One of the most important examples of an ECM component that undergoes remodeling 
and exposure of such matricryptic binding sites is the protein vitronectin.  Vitronectin, 
which is a glycoprotein found predominantly in circulation, becomes deposited into the 
ECM of tissues following injury or tumor mestastasis by an unknown mechanism.   
A working hypothesis of this laboratory suggests that multimerization of vitronectin is a 
physiologically-triggered event that leads to the conversion of plasma (monomeric) 
vitronectin into an adhesive form that readily associates with tissues.  The work presented 
here tests the proposal that interactions with certain biological ligands (here PAI-1) result 
in the conversion of plasma vitronectin to an ECM-associated form that exhibits altered 
adhesive properties.  We suggest that this conversion results from a step-wise assembly 
of vitronectin/ligand complexes that via multivalent interactions with matrix components 
(like glycosaminoglycans) and cell-surface receptors (like integrins and urokinase 
receptor) becomes tissue-associated.  Here, the adhesive nature of vitronectin can be 
utilized during processes like cell adhesion, migration, and invasion. 
2
  To familiarize the reader with the subject matter of this work, below is an overview of 
the structural and functional properties of vitronectin.  This section leads into defining the 
scientific problem to be addressed, followed by a description of the working hypothesis 
and experimental objectives.  
 
Discovery of Vitronectin as an Adhesive Component of Blood 
 Prior to the discovery of vitronectin, it was widely known that blood serum could be 
used to support the binding and activities of many cell types.  Partial separations of serum 
lead to the discovery of a major component that served to support cells in culture [6-10].  
This newly-discovered component was first named “serum spreading factor” [6] and 
“epibolin” [8] – an name given to reflect the ability of this component to support 
epithelial cell spreading and epiboly.  In the years that followed, the serum component 
became widely known under the name vitronectin “on the basis of its binding to glass and 
its adhesive properties [9].”   Since its discovery, vitronectin has become appreciated as 
the main adhesive component in serum that supports cell attachment and proliferation in 
culture.  Over the past 20 years, the ability of vitronectin to support cell adhesion has 
become more and more recognized as a key function that the protein serves in both blood 
circulation as well as in the ECM of tissues. 
  
Structural Organization and Ligand-Binding Sites of Vitronectin 
 As will be discussed in the section to follow, vitronectin is a multifunctional protein 
that plays part in many diverse biological functions including development, wound 
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 healing, and cancer.  This property of vitronectin is largely owed to the ability of the 
glycoprotein to interact with a large list of biological ligands.  This ability is linked to a 
complex molecular organization, which has been elucidated by sequencing human and 
rabbit cDNAs and by analyzing the exon-intron-organization of the human vitronectin 
gene [11-15].  From this, vitronectin can be organized into four structural domains that 
include: the somatomedin B (SMB) domain, the connecting segment, the central domain, 
and the C-terminal heparin-binding domain (Figure 1-1).  Binding sites within these 
domains are responsible for interactions with various physiological ligands including 
PAI-1, heparin, and the thrombin-antithrombin III complex, which have been determined 
using techniques like limited proteolytic degradation, peptide mapping, 
immunochemistry methods, domain swapping, and site-directed mutagenesis.  Structural 
studies of vitronectin have been carried out using computational modeling, NMR, and x-
ray crystallography.  The binding and structural properties mentioned here and how they 
relate to each of the four structural domains of vitronectin are outlined below. 
 
 The Somatomedin B Domain—The amino terminal segment of vitronectin comprising 
amino acids 1-44 is identical in sequence to the plasma protein somatomedin B (SMB), a 
protein with no known function and most likely derived from limited proteolysis of full-
length vitronectin [16]. The SMB domain of vitronectin contains high-affinity binding 
sites for two important fibrinolytic factores, PAI-1 and uPAR [17-21].   
 An interesting feature of the SMB domain is the presence of eight highly-conserved 
cysteine residues that are interlinked through disulphide bonds, predicting an intricate 
4
Fig. 1-1. Domain organization of vitronectin. Structural domains include the SMB domain, the connecting segment, 
the central domain, and the heparin-binding C-terminal domain.  Shown at top at the proposed binding sites for several 
ligands of vitronectin.  Cysteines that are disulfide-linked are shown.  Cysteine residues 196 and 411 (in boxes) are 
have free sulfhydryls that are buried in the native structure.  The oval with minus signs represents the acidic region in 
the connecting segement and the one with plus signs represents the arginine/lysine-rich polycationic region of the 
heparin-binding domain.  Also shown are sites for sulfation, phosphorylation, and N-linked glycosylation, as well as the 
proteolytic cleavage site that in related to the 2-chain form of vitronectin.  
SMB
Domain
(1-44)
Connecting
Segment
(45-130)
Central
Domain
(Hemopexin-like Repeat I)
(131-342)
C-terminal Heparin-
Binding Domain
(Hemopexin Repeat II)
(343-459)
RGD
Sequence
(45-47)
N----C5---C9---------C19-C21---C25-----C31C32------C39 --
(8 S-S interlinked Cysteines)
- - - - -
2-Sulfation sites (Tyr56/Tyr59)
2-Phoshorylation sites (Thr50/Thr57)
N-gly (Asn67) N-gly (Asn150) N-gly (Asn223)
Cys137  Cys161
S-S
Cys274                                                             Cys453
S-S
Cys411  Cys196  
++++ 
2-Phoshorylation sites (Ser362/Ser378)
Proteolytic
Cleavage site 
(Arg379-Ala380)
PAI-1
uPAR
Integrins
T-AT III complex
Collagen
Plasminogen
Heparin, Integrin αVβ5, GAGs, Complement,
Syndecan, Collagen, uPAR, PAI-1
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 compact structure [16,22].  The sequential positioning of the cysteines within the SMB 
domain – Cys5-Cys9-Cys19-Cys21-Cys25-Cys31-Cys32-Cys39 – is found in several other 
proteins, including megakaryocyte-stimulating factor (MSF), plasma cell membrane 
glycoprotein PC-1 , autotoxin (ATX), and tumor cell surface antigen gp130, suggesting 
that this domain represents a highly-conserved structural fold [23].  Using alanine-
scanning mutagenesis, Deng et al. [23] demonstrated that each of the eight conserved 
cysteines within the SMB domain were critical in the binding and stabilization of PAI-1 
in its active form.  These observations indicate that correct disulfide linkages in the SMB 
domain are required for PAI-1 binding.  To carry this analysis further, techniques like x-
ray crystallography, NMR, and disulfide mapping are currently being applied to 
understand the role that these disulfide linkages play in the tertiary structure of the PAI-1-
binding SMB domain of vitronectin. 
  Recently, Kamikubo et al. [24] identified the disulfide bonds formed between cysteines 
in a recombinant form of the SMB domain of human vitronectin.  Their findings 
suggested that the disulfide bonds are linked in an uncrossed, linear pattern, as: Cys5-
Cys9, Cys19-Cys21, Cys25-Cys31, and Cys32-Cys39.  In contrast, x-ray crystallographic 
studies of SMB domain in complex with PAI-1 suggested a crossed pattern of disulfides 
(Cys5-Cys21, Cys9-Cys39, Cys19-Cys32, and Cys25-Cys31) that forms a novel disulfide-
bonded “knot” [25].  Unfortunately, both of these reports must be taken with caution as 
they are based on information collected using recombinant (made in E. coli) forms of the 
SMB domain.  
6
  Recent studies from this laboratory investigating the structure and disulfide 
arrangement of the SMB domain provide a much more convincing picture by evaluating 
these features using SMB domain isolated from human plasma vitronectin [26,27].  
Combined approaches using NMR, limited proteolysis, and mass spectrometry suggest a 
crossed disulfide arrangement with the following assignments:  Cys5-Cys9, Cys19-Cys31, 
Cys21-Cys32, and Cys25-Cys39.    
 Until recently, no experimentally-solved structure for vitronectin had been reported.  As 
will be described later, vitronectin is extremely labile and prone to multimerization, 
making it difficult to crystallize for x-ray diffraction studies.  The first reported structure 
for vitronectin came in July of 2003 when Robin Carrell’s research group at Cambridge 
University (UK) presented a crystal structure for the SMB domain of vitronectin bound to 
active PAI-1 with an rmsd value of 2.3 Ǻ [28].  The presented SMB structure represents a 
novel protein fold, with the only secondary structure of the SMB domain being a single-
turn α-helix and a single-turn 310-helix.  The co-structure of SMB with PAI-1 
demonstrates a potential mechanism through which vitronectin can bind and stabilize 
PAI-1 in its active conformation.  This proposed mechanism involves the binding of the 
SMB domain across the E and F helices of PAI-1, which prevents a sliding movement of 
strands 1 and 2 of the main β-sheet.  The movement of these strands is associated with 
the conformational transition of PAI-1 to its latent inactive form, and by preventing this 
movement the SMB domain of vitronectin stabilizes the active conformation of PAI-1.  
Interpretations of these findings must be taken with caution as again the structure 
presented is that for a recombinant form of the protein [28]. 
7
  Our laboratory recently provided the first solution structure of the SMB domain at 2.29 
Ǻ using 2-dimentional NMR methods to evaluate the domain that was isolated directly 
from plasma vitronectin [27].  These findings were similar to those reported from the x-
ray diffraction study describe above, in which the SMB domain contains only 2 elements 
with a secondary structure.  Again these structures consisted of a single-turn α-helix 
(spanning residues 26-30) and a loosely defined 310 helix (spanning residues 36-38) with 
the remainder of the SMB domain comprised of loops, some of which appear to be 
flexible [27].  However, the two structures solved by these different methods do not 
superimpose well, with different directional orientations of the α-helix in relation to the 
310 helix, resulting in an RMSD between the two structures of greater than 8 Ǻ [27,28].  
These differences may reflect variations in the methods used (x-ray crystallography 
versus NMR), the form of SMB domains used (recombinant versus human forms), and/or 
the type of sample analyzed (SMB domain in complex with PAI-1 versus the SMB 
domain in its isolated form).  Interestingly, both structural determinations were in 
agreement with the findings of Deng et al. [23] that demonstrated the requirement for 
specific residues (Asp22, Glu23, Leu24, Tyr27, and Tyr28) in the binding and stabilization of 
PAI-1.  Both solved structures demonstrate that these residues are properly aligned on the 
α-helix of the SMB domain for optimal binding to PAI-1.  
 
 The Connecting Segment—Following the SMB domain, residues 45 through 130 make 
up what is known as the connecting segment, or linker region of vitronectin [16].  
Directly adjacent to the SMB domain at the N-terminal end of the connecting segment is 
8
 an arginine-glycine-aspartate (RGD) sequence (residues 45-47) that mediates the 
attachment and spreading of cells to the ECM through the binding to specific integrin 
receptors [29,30]. Indeed, site-directed mutagenesis of the RGD sequence abolishes cell 
adhesion to vitronectin [31].  Several integrins, including αVβ1, αVβ3, αVβ5, and 
GPIIbIIIa, have been shown to mediate cell adhesion by interacting with the RGD 
sequence on vitronectin [32-34]. 
 Adjacent to the RGD sequence, the connecting segment of vitronectin has a stretch of 
acidic amino acids (residues 53-64), including two sulfated tyrosine residues (Tyr56 and 
Tyr59) [35].  This acidic region is important in the binding of vitronectin to the thrombin-
antithrombin III and collagen [36,37].  It has been suggested that the acidic region of 
vitronectin also plays a role in the binding and neutralization of a poly-cationic (heparin-
binding) domain on the opposite end of the protein, in a manner that serves to stabilize 
the 3-dimensional structure of vitronectin. Within the acidic region of vitronectin there 
are two phoshorylation sites, Thr50 and Thr57, which are specifically phosphorylated by 
casein kinase II (CKII) [38].  Phosphorylation by CKII was shown to promote cell 
adhesion onto vitronectin, via the αVβ3-phosphatidylinositol 3-kinase (PI3K)/protein 
kinase B (PKB)  pathway [39].  Downstream of the acidic region, the connecting segment 
of vitronectin contains a site (residue Asn67) for N-linked glycosylation and a putative 
cross-linking site (Gln93) for transglutaminase [40,41].  Although there is no reported 
structure for the connecting segment of vitronectin, this segment of the protein is 
predicted to be in a loop conformation by the secondary structure prediction program 
PHD [42].    
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 The Central Domain—Residues 131-342 comprise the central domain of vitronectin, 
which together with the C-terminal domain show strong homology to hemopexin, a 
heme-binding protein found in plasma [16,22].  Hemopexin contains a symmetrical two-
domain structure connected by a flexible hinge region, with each domain containing four 
homologous repeats [43].  Vitronectin contains only six typical hemopexin repeats with a 
putative hinge region at Pro268.  The central domain of vitronectin contains four of these 
repeats, and threading algorithms predict this domain to adopt a full four-bladed β-
propeller fold, similar to that seen in gelatinase A, collagenase, and hemopexin [42].  The 
central domain contains four cysteine residues in a mixture of reduced and oxidized 
forms [44,45].  Two cysteine residues, Cys137 and Cys161, form an intra-domain disulfide 
bridge, whereas Cys 274 forms an inter-domain disulfide bridge with Cys453 located within 
the C-terminal domain of vitronectin.  This inter-domain bridge serves to link an 
endogenously-cleaved 10-kDa fragment from the C-terminus of vitronectin with the rest 
of the molecule (described in next section).  The final cysteine (residue 196) of the 
central domain is free and evidently inaccessible in the native form of vitronectin [44,45].  
The central domain also contains two N-linked glycosylation sites at Asn150 and Asn223.  
The only ligand-binding site attributed to the central domain is for plasminogen (residues 
332-348), which spans over into the C-terminal domain of vitronectin [22]  Aside from 
the information gained from computer modeling described below, no structure for the 
central domain has been solved experimentally.   
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  The C-Terminal Domain—The C-terminal domain (residues 347-459) of vitronectin 
contains a basic region spanning approximately 30 amino acids (residues 348-376) rich in 
arginine and lysine residues.  This positively-charged region of vitronectin contains two 
heparin-binding consensus sequences and plays a role in the binding and neutralization of 
this important anti-coagulation factor.  Interestingly, this heparin-binding domain is also 
responsible for the binding of vitronectin to several other ligands, including  the integrin 
αVβ5 [46], sulfated glycosaminoglycans [47], syndecan [Wilkins-Port, 2004 #166], 
complement components C5b, C6, C7, C8, C9 [48], plasminogen [49], PAI-1 [49-51], 
uPAR, and collagen [37,52].   
 Directly downstream of the heparin binding domain is a proteolytic cleavage site 
between Arg379 and Ala380 [53,54].  Susceptibility of cleavage at this site is dependent on 
the presence of methionine or threonine at position 381 [53,54].  Cleavage occurs by an 
unidentified protease and results in the release of 10-kDa fragment of vitronectin [55].  
As mentioned above, Cys453 is disulfide-linked to Cys274 in the central domain, and this 
bond holds the 10-kDa fragment of vitronectin to the remaining molecule.  A second 
cysteine (Cys411) within the C-terminal domain is free and buried [42]. 
 Within the C-terminal domain of vitronectin, there are two potential phosphorylation 
sites at serines 362 and 378.  Protein kinase C (PKC) phosphorylates at Ser362 which 
causes an attenuation in the cleavage of vitronectin by plasmin [56].  Protein kinase A 
(PKA), which is released from platelets upon activation, specifically phosphorylates 
vitronectin at Ser378 [57].  Circular dichroism studies demonstrated that phosphorylation 
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 by PKA at Ser378 alters the conformation of vitronectin and results in decreased binding 
of the protein to PAI-1 and plasminogen [58].   
 The C-terminal domain contains two of the six hemopexin-like repeats found within 
vitronectin.  As with the central domain, the only structural clues regarding the C-
terminal domain of vitronectin come from computer modeling.  Using threading, Xu et al. 
[59] predicted the C-terminal domain to form one-half of a 4-bladed β-propeller fold.  
Inter-domain docking of the central and C-terminal domains using GRAMM 
demonstrated the presence of a groove lined with known heparin-binding residues. 
 
Biological Functions of Vitronectin 
 Vitronectin, through its ability to interact with both cells and proteins that control 
coagulation, fibrinolysis, and humoral defense, represents a unique regulatory link 
between adhesion and proteolytic cascades that are involved in the maintenance of 
homeostasis.  Vitronectin has been linked to the regulation of  several biological 
processes (Figure 1-2), several of which are described below. 
 
 Vitronectin is an Adhesive Component of the Pericellular Environment—Vitronectin 
has long been known for its ability to mediate cell adhesion and proliferation.  Early 
immunofluorescence studies demonstrated the presence of vitronectin in focal adhesions 
of cells cultured in media supplemented with serum [13].  In fact, the majority of cell 
attachment activity in serum-containing media is mediated by vitronectin, and to a lesser 
extent by fibronectin, another adhesive protein found in circulation and tissues. As 
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Vitronectin
ECM Anchoring
(GAGs, Syndecan, Collagen)
Cell Adhesion & Spreading
(Integrins, uPAR) Blood Coagulation(T-AT III complex, Heparin)
Fibrinolysis
(PAI-1, uPAR)
Immune defense
(Components of Complement)
Fig. 1-2. Vitronectin is linked to many biological functions. Vitronectin mediates 
contacts that bridge cells to the surrounding ECM, and in a unique way serves to link 
these cell-matrix associations with localized proteolytic cascades that are involved in 
a diverse list of humoral defense mechanisms.
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 mentioned before, vitronectin contains binding sites for both cell-surface receptors and 
components of the ECM, and therefore represents a powerful bridging agent in the 
association of cells with their surrounding microenvironment.    
 Vitronectin promotes cellular adhesion, spreading, and migration of a wide variety of 
cell types, including fibroblasts, endothelial cells, megakaryocytes, platelets, and certain 
tumor cell lines [60].  These different cells lines all can mediate attachment to tissues via 
the presence of integrins on the cell surface.  Integrins are a major group of versatile 
receptors that serve in both adhesive and signaling functions.   Integrins are composed of 
non-related α- and β-subunits that are associated by non-covalent interactions that are 
promoted by divalent cations.  The integrin superfamily displays a wide functional 
diversity, owed to the variable subunit composition of each receptor.  Integrins known to 
associate specifically with vitronectin include αVβ1, αVβ3, αVβ5, and GPIIbIIIa [30,60-
66],  As mentioned before, binding of integrins to vitronectin is mediated mainly through 
an RGD sequence located at the N-terminus of the protein.  Growing evidence indicates 
that there are certain signaling pathways associated with the binding of vitronectin to 
several different integrins, which can alter protein expression and cellular behaviors like 
migration and invasion. 
 By spanning the plasma membrane, integrins serve to connect the intracellular 
cytoskeleton to the extracellular environment.  In this way, integrins use mechanical 
stimuli, such as adhesion to the ECM, to transduce information into biochemical signals 
that can profoundly alter cellular processes link to adhesion, proliferation, migration, 
invasion, and even detachment.  Hapke et al. [67] recently reported that the interaction of 
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 vitronectin with αVβ3 alters the expression of the urokinase plasminogen activation 
system in human ovarian cancer cells.  This study demonstrated that vitronectin binding 
to αVβ3 resulted in a down-regulation in the expression of uPA and uPA, while causing 
an increase in PAI-1 levels by 4-fold. Another important finding demonstrates that αVβ3 
binding to vitronectin can cause an increase in the production of the anti-apoptotic factor 
Bcl-2, an event that correlated with protection from apoptosis [68].  Lastly, Tsou et al. 
showed that vitronectin binding to both αVβ3 and αVβ5 on human microvascular 
endothelial cells resulted in an increase in several growth factor receptors, including 
FGFR and VEGFR.    
 Another way that vitronectin mediates cell adhesion is by interacting with the GPI-
linked receptor, uPAR [60,69,70].  Vitronectin has been shown to bind uPAR on the 
surface of endothelial cells, monocytes, and myeloid cells, and fibroblasts, promoting 
their adhesion to the ECM . In fibrinolysis, uPAR serves to focus the proteolytic activity 
of bound plasminogen activators at the leading edge of migrating cells.  Attachment of 
cells to vitronectin via uPAR has been shown to coordinate wound healing, tumor 
migration, and invasiveness.  As in other matrix proteins, such as fibronectin and 
fibrinogen, vitronectin contains binding sites for both cell-surface receptors and ECM 
molecules.  Through interactions with glycosaminoglycans and collagen [47,71-76], 
vitronectin can associate with the ECM and support an adhesive microenvironment for 
cellular activities like adhesion and migration through integrin receptors and uPAR.  
Discuss in depth the role of vitronectin as a integrating part of the ECM; evidences of 
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 what it can bind, that this binding is related to conformation changes in vitronectin, and 
again state that the “activation” trigger is unknown. 
 
 Vitronectin Regulates Thrombosis and Fibrinolysis—Arguably, the most important 
biological parter of vitronectin is the anti-fibrinolytic protein, PAI-1.  PAI-1 is a serine 
protease inhibitor (serpin) and serves as the main regulator of the plasminogen activators, 
uPA and tPA, during tissue remodeling events like wound healing and cancer.  uPA and 
tPA are responsible for the cleavage of blood plasminogen into its active form, plasmin, 
which is a non-specific protease that aggressively degrades protein matrices, including 
fibrin clots associated with wounded tissue.  Serpins represent a superfamily of inhibitors 
that share a common structural organization and a common mechanism of inactivation of 
their target enzymes.  As shown in Figure 1-3, PAI-1 adopts a unique structure with 
features that are pertinent to its inhibitory mechanism.  The image on the left (panel A) 
shows PAI-1 in its active conformation, with a common reactive center loop (RCL) that 
protrudes outward from the main body of the protein which is made up of a β-sheet core.  
In all inhibitory serpins, the RCL serves as a pseudosubstrate for the partner protease.  
When tPA or uPA act on the RCL of PAI-1, a 1:1 stoichiometric complex is formed with 
the rapid formation of a covalent bond between the protease active site (serine hydroxyl) 
and the main-chain carbonyl at the P1 residue on the RCL of PAI-1. The covalent 
complex of uPA/tPA and PAI-1 undergoes a dramatic conformation rearrangement 
leading to loop insertion to the β-sheet core and irreversible inhibition. 
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Active PAI-1                   Latent PAI-1
T1/2 = 90 min
RCL
RCL
insertion
A                                  B
Fig. 1-3. Comparison of active and latent forms of PAI-1. Structure of active 
PAI-1 solved for the stable variant 14-1B-PAI-1.  The regions that undergo the 
largest conformational shifts are indicated in dark gray.  These include the reactive 
center loop (RCL, residues 331-357), which moves from an exposed position as 
“bait” for the target protease to a sequestered position at the central strand of the core 
β-sheet.  This structural reordering requires movement of the RCL around the C-
terminal face of PAI-1 with an outward shifting of strands 1A, 2A, and 3A, as well as
a “hinging” motion by the small coil-turn-helix domain at the lower center of the 
structure.   [Reconstructed from Figure 1 of Biochemistry, Vol. 39, No.29 (2000) 
page 8461 (add ref #)]
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  PAI-1 is a unique serpin in that its active, inhibitory conformation (Fig. 1-3 panel A) is 
relatively unstable and spontaneously converts to an inactive, latent form (panel B).  
Under physiological conditions, human active PAI-1 has a half-life of ~90 minutes [77].  
The conversion to latency by PAI-1 is characterized by insertion of the PAI-1 RCL into a 
central β-sheet with the body of the protein [78].  As mentioned before, vitronectin 
binding to PAI-1 restricts the sliding movement in the central β-sheet that facilitates the 
conversion of PAI-1 to the inactive form.  As such, binding of vitronectin causes a 2-4 
fold increase in the half-life of active PAI-1 [77], making vitronectin an important co-
factor in the regulation of plasminogen activation.  Interestingly, vitronectin binding to 
PAI-1 also endows the inhibitor with a new specificity for the clotting enzyme thrombin, 
although the physiological significance of induced specificity of PAI-1 for thrombin is 
not known. 
 
 Vitronectin Regulates the Immune Response of Complement—The humoral immune 
response system in humans is supported by the complement system, whose activation via 
proteolytic cascade mechanisms leads to the lytic destruction of antibody-opsonized 
invasive cells or microorganisms.  Steps leading to cellular lysis involve the interactions 
of several complement components, including C5b, C6, C7, C8, and C9, that join 
together to form a membrane attack complex [79].  These hydrophilic components form 
complexes that are amphiphilic and insert into the membrane of attacked cells.  In a final 
step involving polymerization of component C9, a resulting lytic pore is formed.     
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  Vitronectin has been shown to interact with many of the complement components, as 
well as the step-wise complexes that the component form, resulting in water-soluble 
complexes that cannot insert into the cell membrane or are prevented from polymerizing 
into an active lytic pore.  The ability of vitronectin to inhibit complement complexes 
from forming most likely reflects a protective function for vitronectin, which serves to 
protect from innocent bystander cell lysis of host tissue. 
        
 Vitronectin and Embryonic Development—Through its ability to regulate such a 
diverse number of functional pathways, vitronectin serves as an integral part of several 
normal and pathological processes.  The broad functional activities of vitronectin, 
especially those related to cell/matrix adhesion and vascular hemostasis, suggests that the 
protein may play a critical role in mammalian development.  Several studies have linked 
vitronectin to the developing nervous system at early stages of mouse organogenesis.  
Studies carried out by Martinez-Morales and Rodreiguez-Tebar [80,81] tested this 
hypothesis by evaluating the role of vitronectin in the developing chick retina. Ventral 
neural tube extracts from chick embryos, vitronectin promoted the generation of motor 
neurons.  Neugebauer [82] confirmed these results promoted neurite outgrowth during 
retinal development, and that this activity was dependent on the interaction of vitronectin 
with the cell-surface integrin αVβ1.   
 Pons [83] demonstrated the activity of vitronectin in the developing cerebellum and 
found that vitronectin regulates neuronal proliferation and differentiation, and that this 
regulation was dependent on Sonic hedgehog and that vitronectin stimulated the 
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 phosphorylation of cyclic-AMP reponse element binding protein (CREB).  This event 
was also shown to be integrin-dependent.. Involvment in bone development [84].  
Sumida [85] showed that vitronectin was important during heart development, where the 
protein was proposed to regulate endocardial cell migration in the developing chick heart.  
Isahara [86]demonstrated that during development vitronectin regulated interactions 
between developing peripheral nerves and blood vessels.  In these studies, they 
demonstrated that vitronectin promoted neutrite outgrowth by dorsal root ganglion cells 
onto vascular endothelial cells. Interestingly, mice deficient in vitronectin demonstrate 
normal development, fertility, and survival [87].  These studies do not, however, negate 
the above findings or the probability of vitronectin’s role in development, but most likely 
indicate that the functions of vitronectin may partially overlap that of other adhesive 
matrix components that may compensate for the absence of vitronectin.  
 
 Vitronectin in Wound Healing and Disease—The process of coagulation is a 
complex mechanism that involves many components that come together in a highly 
regulated manner to prevent the excessive loss of blood and initiate tissue repair.  
Coagulation occurs through an accelerated proteolytic cascade that ultimately leads to the 
conversion of fibrinogen into its insoluble counterpart, fibrin.  The enzyme responsible 
for the catalytic conversion of fibrinogen into fibrin is the serine protease, thrombin.  
Following conversion, fibrin readily associates with platelets and ECM at the site of 
injury, forming a primary hemostatic plug.  In this scenario, thrombin is tightly regulated 
by the protease inhibitor anti-thrombin III (AT III), which forms a stable complex with 
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 thrombin.  Although AT III inhibition of thrombin is irreversible, the rate of inhibition is 
slow.  However, heparin, and other glycosaminoglycans found in the vascular space, 
form interactions with AT III that induce conformational changes leading to enhanced 
reactivity towards thrombin.  In doing so, heparin serves as a powerful anti-coagulating 
agent, causing a down-regulation in the formation of insoluble fibrin. 
 Vitronectin can control the coagulation process by directly interacting with heparin.  
This interaction “neutralizes” heparin by impeding its binding to either thrombin and/or 
AT III.  Thrombin remains active and clot formation is favored, and in this way 
vitronectin serves as a pro-coagulating factor during wound response.  Interestingly, 
vitronectin directly interacts with the thrombin-AT III complex, but the exact functional 
significance of this event is unknown.  Studies have shown that vitronectin/thrombin-AT 
III complexes are rapidly cleared from circulation, suggesting a potential role in tissue 
deposition and remodeling [88,89].  The diverse functional capabilities of vitronectin, 
especially those related to cell adhesion and pericellular proteolysis, make the protein a 
perfect candidate for aiding in the body’s response to pathological events like wounding 
and disease.    
 
Distribution of Vitronectin in Circulation and Tissues 
 Vitronectin is present predominantly as a monomer in circulation at a concentration of 
0.25-0.45 mg/ml (~4-7 micromolar) [13], and constitutes approximately 1 percent of total 
plasma proteins.  Although the hepatocyte is the major vitronectin-producing cell type, a 
limited number of other cells, including blood-derived (cultured) monocytes, 
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 macrophages, and megakaryocytes, have been reported to synthesize and secrete 
vitronectin [13,90].  However, drastic reductions in plasma levels of vitronectin are 
observed in patients with severe liver failure, indicating that the liver is the major source 
of circulatory vitronectin. 
 A second circulatory pool of vitronectin is found with platelets, where it exists in 
releasable form within α-granules.  Upon activation during thrombosis, platelets rapidly 
release vitronectin such that their ability to adhere to the surrounding tissue is enhanced.  
Interestingly, vitronectin found within platelets is in a multimeric form and is 
immunologically similar to the form of vitronectin adopted following denaturation.  
 In addition to its presence in circulation, vitronectin is also found associated with the 
ECM of tissues.  Although immunohistochemical studies demonstrate that vitronectin is 
normally absent from most tissues, the protein becomes deposited at sites of injury and 
disease.  Examples of this (see Table 1-I) include vitronectin deposition in 
diseased/injured tissues of brain [91], skin [92-94], kidney [95-103], liver [102,104-107], 
vascular system [108-111], lymph [112], ovary [113], breast [107,114,115], bone [112], 
colon [114], and pancreas [116].  In these various tissues, vitronectin is assumed to take 
on an adhesive role and, like the platelet form, is conformationally distinct from the 
circulating (monomeric) form of the protein. The absence of detectable vitronectin 
biosynthesis in tissues suggest that there must be a specific mechanism(s) that mediates 
the uptake of circulating vitronectin into tissues. 
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Table 1-I.  Deposition of vitronectin in injured/disease tissue. 
 
Tissue type;          Co-Localized  
 Injured/Diseased Localization Pattern     Binding Partners  Refs.    
                
Brain 
 Cerebral amyloid plaques in Alzheimer’s Disease    αV Integrin Subunit  Eikelenboom et al. 1994 (91) 
 
Skin 
 Solar elastosis and dermal amyloid deposits in certain skin diseases N/A    Dahlback et al. 1988 (92) 
 Lesions In discoid lupus erythematosus and dermatitis herpetifomris Complement   Dahlback et al. 1989 (93) 
 Lesions in lichen planus pemphigoides     Complement   Hintner et al. 1990 (94) 
  
Kidney 
 Glomerular deposits in membranous nephropathy    PAI-1, tPA   Nakamura et al. 1996 (96) 
               Complement, αVβ3  Ogawa et al. 1994 (97) 
 Lesions in glomerulonephritis      Complement   Murphy et al. 1989 (99) 
                   Okado et al. 1993 (98) 
 Lesions in renal infarction/ischemia     Complement   Vakeva et al. 1995 (100) 
 Sclerotic lesions in childhood IgA nephropathy    Complement   Takahashi et al. 1995 (101) 
 Amyloid deposits in amyloid A and light chain type amyloidosis  N/A    Dahlback et al. 1987 (95) 
 Immunoglobulin glomeruli deposits     Complement   Inuzuka et al. 1997 (102) 
 Lesions in diabetic nephropathy and arterionephrosclerosis  Complement   Falk et al. 1987 (103) 
 
Liver 
 Areas of chronic and mature fibrosis in cirrhosis    N/A    Koukoulis et al. 2001 (104) 
 Hepatic fibrosis in liver disease      PAI-1    Inuzuka et al. 1997 (105) 
 Lesions in chronic hepatitis and cirrhosis     N/A    Kobayashi et al. 1994 (106) 
                   Jaskiewicze et al. 1993 (107) 
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Table 1-I.  Continued. 
 
Tissue type;          Co-Localized  
 Injured/Diseased Localization Pattern     Binding Partners  Refs.    
 
Vascular 
 Heart lesions in myocardial infarction     Complement   Vakeva et al. 1993 (108) 
 Fibrous tissue and plaques in atherosclerosis    Complement   Niculescu et al. 1987 (109) 
                   Van Akon et al. 1997 (110) 
Neointimal atherosclerotic arteries      Thrombin, PAI-1  Stoop et al. 2000 (111) 
 
Lymph 
 Fibrotic lymph nodes in Hodgkin’s disease/metastatic carcinomas N/A    Reilly et al. 1988 (112) 
 
Ovary 
 Differentiated ovarian carcinomas       αVβ3    Carreiras et al. 1996 (113) 
 
Breast 
 Infiltrating duct carcinomas       N/A    Loridon-Rosa et al. !988(114) 
                   Aaboe et al. 2003 (115) 
                   Jaskiewicze et al. 1993 (107) 
 
Bone 
 Myelofibrotic bone marrow       N/A    Reilly et al. 1988 (112) 
 
Colon 
 Colonic adenocarcinomas       N/A    Loridon-Rosa et al.1988(114) 
  
Pancreas  
 Pancreatic carcinomas       αV Integrin Subunit  Linder et al. 2001 (116) 
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  Statement of Scientific Problem—The mechanism that causes the conversion of 
circulating (monomeric) vitronectin to a tissue-associated form is currently unknown.  In 
addition, the potential ramifications of the association with vitronectin are poorly 
understood.  Considering pathological states such as injury, inflammation, and cancer, 
these questions surrounding vitronectin are important to explore. 
 
Conformational Flexibility of Vitronectin:  
Testing the Mechanisms of Activation 
 
 Early studies demonstrated that human plasma contains two structurally and 
functionally distinct forms of vitronectin.  Physical characterization of the two forms 
demonstrated that the least abundant form (representing less that 2% of the total 
vitronectin in plasma) is in a higher-order form, consisting of 6.5 S aggregates with a 
Stokes radius of 5.6 nm, compared to the most abundant form isolated from plasma, 
which is a 4.2 S monomer with a Stokes radius of 3.9 nm.  Functional assays 
demonstrated that only the 6.5 S multimeric form of vitronectin associated with heparin, 
and this form also diplayed increased reactivity (as compared to monomeric vitronectin) 
towards anti-vitronectin antibodies.  This studies indicated that vitronectin can exist in at 
least two distinct forms that display important differences in conformation and function, 
but that the major form found in circulation is monomeric and “silent” in certain binding 
activities. 
 It was later discovered that denaturation of vitronectin with chaotropic agents, heat 
treatment, and acidification greatly increased its reactivity with heparin.  A number of 
conformationally sensitive antibodies and ligands of vitronectin, including collagen, 
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 glycosaminglycans, β-endorphin, PAI-1, integrins, and the urokinase/uPAR receptor, 
were all shown to interact preferentially with the conformationally altered, denatured 
form of vitronectin [90].  Research from this laboratory demonstrated that denaturation of 
vitronectin results in the formation of homo-multimers that display enhanced binding to 
specific ligands, such as heparin, through the generation of multivalent interactions that 
arise following an induced “clustering” of individual low-affinity binding sites [117,118].   
 Finally, complex formation of vitronectin with several ligands, including PAI-1, 
thrombin-antithrombin III, and complement C5b-C9, also induces conformational 
changes in vitronectin that are similar to those induced by artificial means [119-121].  
These changes are likewise associated with the multimerization of vitronectin into 
multivalent complexes that diplay both structural and functional divergence from the 
non-bound, monomeric form.  What is the biological significance of vitronectin 
multimerization?  Is ligand-induced multimerization a physiological mechanism 
that regulates the localization and functions of vitronectin?  Referring to Figure 1-4, 
there is an artificial model and a physiological model, which we adopt for studying the 
potential mechanism for the activation of vitronectin.  Considering the lability of 
vitronectin, a plausible explanation for how the protein becomes deposited into the ECM 
of tissues is through a ligand-induced mechanism.  Binding of vitronectin to biological 
co-factors like PAI-1 and complement complexes would lead to formation of higher-
order complexes that can readily associate with the ECM and nearby or migrating cells.  
Supporting this idea is the observed colocalization of vitronectin with ligands like PAI-1 
and complement in areas of fibrosis, necrosis, and inflammation [102,111,122-126].   
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A. Artificial model of vitronectin “activation”
B. Physiological model
Chemical daturation
Heat denaturation
Acidification
►Multimerization
►Altered antibody recognition
►Enhanced heparin binding
►Enhanced cell/matrix binding
PAI-1
T-AT
Complement factors
►Multimerization
►Recruitment to tissues as a pro-adhesive form
►Facilitate cell adhesion/migration
►Regulate matrix remodeling via proteolytic
cascades
Tissue injury/Inflammation
Cancer
Complement
Fig. 1-4. Models for evaluating the structural/functional activation of 
vitronectin. Much information regarding vitronectin has been gained evaluating a 
more non-physiological model (Panel A).  Focus in now being made on more 
physiolgically possible mechanisms leading to vitronectin activation (Panel B).
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 Working Hypothesis—PAI-1-binding to vitronectin induces the formation of higher-
order complexes that display altered adhesive properties distinct from the circulating 
(monomeric) form of vitronectin.  These altered adhesive properties arise from the 
induction of multivalent binding sites for both cell surfaces and components of the ECM.  
Formation of vitronectin/PAI-1 complexes follows a step-wise assembly process that is 
dependent on protein concentration and time, ultimately leading to an increased 
accumulation of vitronectin at the cell-matrix interface   
PAI-1 represents a physiological cofactor for the conversion of vitronectin from a 
circulating, monomeric form to a matrix-associated, “activated” form.  PAI-1-binding 
to vitronectin induces the formation of higher-order complexes that display altered 
adhesive properties distinct from the circulating (monomeric) form of vitronectin.  
These altered adhesive properties arise from the formation of multivalent binding sites 
for both cell surfaces and components of the ECM.  Formation of vitronectin/PAI-1 
complexes follows a step-wise assembly process that is dependent on protein 
concentration and time, ultimately leading to an increased accumulation of vitronectin 
at the cell-matrix interface.  
     
 Research Aims—To address the working hypothesis stated above, the following 
research objectives were designed and carried out.  A schematic in Figure 1-5 illustrates 
the overall system of studies to be carried out and the questions addressed.  
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Assembly Process
(Chaps. 2 & 4)
VN
PAI-1
+
4:2
PAI-1:VN
Complex
?
Functional effects
(Chaps. 2 & 3)
Higher-order
Complexes
Formed
(Chaps. 2 & 4)
?
?
Fig. 1-5. Schematic representing the working model to be investigated. Both 
biological and biophysical studies are designed to evaluate the mechanism and 
functional consequences of PAI-1-induced multimerization of vitronecctin.
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  Aim 1:  To test the effects of PAI-1-induced multimerization on the interaction of 
vitronectin with cell-surface integrins and components of the ECM. 
 The set of studies described in Chapter 2 were designed to carefully monitor the 
formation of higher-order vitronectin/PAI-1 complexes and correlate these findings with 
binding studies using cells and purified components of both cell surface receptors and the 
ECM.  To follow complex formation, mixtures of vitronectin and PAI-1 were analyzed 
by size-exclusion HPLC under various conditions.  In conjunction, complexes were 
tested for their ability to associate with cell surfaces and extracellular matrices in a solid-
phase platform.  These experiments demonstrated a direct correlation between the 
formation of higher-order vitronectin/PAI-1 complexes and enhanced binding of 
vitronectin to both cell surfaces and the ECM.  These findings support a role of PAI-1-
induced multimerization in the deposition of vitronectin at the cell-matrix interface and 
provide a plausible mechanism through which circulating vitronectin is converted to a 
tissue-associated form. 
 
 Aim 2:  To evaluate the effects of PAI-1-induced multimerization of vitronectin in a 
living cell system using human fibroblasts. 
 Studies carried out for Objective 2 (described in Chapter 3) were designed to 
complement the solid-phase binding assays performed for Objective 1.  By utilizing a 
living system, we gain more physiological support regarding our model that 
vitronectin/PAI-1 complexes display adhesive properties that develop through the process 
of ligand-induced multimerization of vitronectin.  The results presented in this chapter 
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 provide new evidence that PAI-1/vitronectin complexes display enhanced interactions 
with human fibroblast monolayers, an event that would be significant during homeostatic 
responses such as wound healing and tissue remodeling.  In these studies, 
vitronectin/PAI-1 complexes displayed enhanced association with cell monolayers and 
cell surface receptors, leading to a greater degree of endocytosis and lysosomal 
degradation of vitronectin compared to the native vitronectin.  These findings were 
monitored using both biochemical assays and immunofluorescence microscopy.  Binding 
of vitronectin/PAI-1 complexes to fibroblast monolayers is shown to be dependent on the 
presence of sulfated glycosaminolglycans and uptake to be partially dependent on cellular 
integrins.  These results provide strong evidence in a living cell system that PAI-1-
induced multimerization can regulate the incorporation of vitronectin into an adhesive 
matrix protein.    
 
 Aim 3:  To evaluate the mechanism of assembly of higher-order vitronectin/PAI-1 
complexes. 
 In the studies presented in Chapter 4, we characterize the biochemical mechanism 
involved in the assembly of higher-order vitronectin/PAI-1 complexes that become 
adhesive in nature.  This characterization ultimately will address the following questions:  
What types of higher-order complexes form as a result of the vitronectin/PAI-1 
interaction?  What is the order of steps leading to the assembly of higher-order 
complexes?  What are the kinetic and binding parameters associated each step?  What is 
the concentration dependence of PAI-1 on complex formation? What molar 
31
 stoichometries for vitronectin and PAI-1 exist for the different species of complexes 
formed?   
 To begin addressing these questions, fluorescence- and hydrodynamics-based 
experiments were carried out to follow the formation of vitronectin/PAI-1 complexes. 
Equilibrium binding assays, using a fluorescently-tagged PAI-1, demonstrate that binding 
of vitronectin to PAI-1 occurs in an allosteric manner, through which two separate PAI-1-
binding sites become occupied.  Sedimentation velocity experiments were used to 
observe the types of vitronectin/PAI-1 that build off the 1:2 and 2:4 (vitronectin:PAI-1) 
complexes that are reported to form [127].  These studies were also used to test the 
effects of time, ionic strength, and protein concentration on the assembly of higher-order 
complexes.  In short, the results described in this chapter provide valuable information 
regarding the step-wise formation of vitronectin/PAI-1 complexes, and give further 
insight into how complex formation between these two proteins may support adhesive 
processes during wound healing and tumor metastasis.   
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 CHAPTER 2 
 
PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 PROMOTES 
THE SELF-ASSOCIATION OF VITRONECTIN INTO COMPLEXES 
EXHIBITING ALTERED INCORPORATION INTO THE  
EXTRACELLULAR MATRIX* 
 
 
*This chapter is a revised version of a manuscript under the same title published in the 
Journal of Biological Chemistry in 2001 by Kenneth H. Minor and Cynthia B. Peterson 
[128]: 
 
Minor, K. H. and Peterson, C. B.  Plasminogen activator inhibitor type 1 promotes the 
self-association of vitronectin into complexes exhibiting altered incorporation into the 
extracellular matrix.  Journal of Biological Chemistry 277 (12): 10337-10345. 
 
My contributions to this paper include: (1) aiding in the development and design of 
experimental goals and procedures, (2) performing all experiments and collections of 
data, (3) analyzing collected data, (4) designing how the results were illustrated, and (5) 
writing and publication of the work in collaboration with my mentor Dr. Cynthia 
Peterson. 
 
Introduction 
 As discussed in the opening chapter, the diverse functionality of vitronectin arises from 
its ability to interact with many biological ligands, including the thrombin-antithrombin 
complex, PAI-1, and components of complement [13,40,88].  In addition to these 
functions, vitronectin is conformationally labile and exists both in circulation and the 
ECM of tissues.  During pathological events such as wounding and disease, we propose 
that circulating vitronectin undergoes structural changes that cause the protein to 
associate with cell surfaces and the ECM of affected tissues.  The mechanism that leads 
to the transition, or “activation”, of vitronectin from a circulating-form to a tissue-
associated form remains unclear.  The underlying hypothesis of this dissertation states 
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 that interactions of vitronectin with certain biological ligands, here PAI-1, result in the 
formation of multimeric complexes that have a propensity to associate with cell surfaces 
and the ECM. 
 PAI-1 binding has been linked to conformational changes in vitronectin, which result in 
the formation of multimeric structures with binding properties different from that of 
monomeric vitronectin [119,127].  Multimeric forms of vitronectin have been shown to 
readily associate with both cell surface receptors and ECM components 
[47,61,118,119,129-132], indicating that multimerization in vivo might be the key step 
leading to the conversion of vitronectin to a matrix-associated form.  Importantly, both 
vitronectin and PAI-1 have been detected co-locally with tissues undergoing wound 
healing or tumor metastasis [102,111,123-126], suggesting that the two proteins serve as 
co-factors in matrix deposition and remodeling. 
 The following studies were designed to monitor the formation of higher-order 
vitronectin-PAI-1 complexes and correlate these findings with binding studies using cells 
and purified components from both cell surfaces and the ECM.  To follow complex 
formation, mixtures of vitronectin and PAI-1 were analyzed by size-exclusion HPLC 
under various conditions.  In conjunction, complexes were tested for their ability to 
associate with cell surfaces and extracellular matrices in a solid-phase platform.  Our 
findings support a role of PAI-1-induced multimerization in the deposition of vitronectin 
at the cell-matrix interface.   
    
 
34
 Materials and Methods 
 Proteins and Antibodies—Native vitronectin was purified from human blood plasma 
using a modified protocol of the method developed by Dahlback and Podack [133,134].  
Human GPIIbIIIa was obtained from Enzyme Research Laboratories.  Human αVβ3 came 
from Calbiochem.  Recombinant human PAI-1 (wild-type) and tPA were obtained from 
Molecular Innovations.  Latent PAI-1 was either prepared by 24-hour incubation of wild-
type PAI-1 at 37 ºC, or it was purchased from Molecular Innovations.  Human ECM and 
Matrigel were purchased from Becton Dickinson.  Polyclonal antibodies against 
vitronectin were generated in rabbits by contract with Rockland Laboratories.  A 
monoclonal antibody specific for PAI-1 was a kind gift of Dr. Tom Podor.  Peroxidase-
labeled secondary antibodies (anti-rabbit and anti-mouse) were obtained from Vector 
Laboratories.  Protein standards used for HPLC came from Amersham Biosciences, Inc.  
Native vitronectin was phosphorylated using [γ-32P]ATP (Amersham Biosciences, Inc.) 
and protein kinase A (catalytic subunit, product of Sigma).  Unincorporated radiolabel 
was removed by a desalting centrifugation step using Bio-Spin 30 columns.  Specific 
radioactivity was determined directly by quantifying vitronectin in a BCA assay (Pierce) 
and measuring radioactivity in a Beckman LS3801 Scintillation Counter.  Specific 
radioactivity was 100,000 cpm/pmol of vitronectin. 
 
 Size Exclusion HPLC—Chromatography of vitronectin/PAI-1 mixtures was carried 
our using a Phenomenex Biosep SEC-S3000 (300 x 7.8 mm) column attached to a 
Hewlett-Packard 1100 series HPLC system.  PBS containing 0.005% (w/v) sodium azide 
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 was used for the reaction and isocratic mobile phase.  Equimolar concentrations of 
vitronectin and PAI-1 were mixed and incubated for various times at 37 ºC.  In some 
experiments, an equimolar amount of tPA was added at the end of the incubation period 
to inactivate PAI-1 and dissociate it from vitronectin.  On occasion, NBD-S119C PAI-1 
was used to explicitly monitor the absorbance of NBD at 494 nm as a probe for PAI-1.  
Samples (50 µl) were injected onto the pre-equilibrated size-exclusion column and 
chromatographed at room temperature at a flow rate of 1 or 0.5 ml/min.  Absorbance was 
detected directly in the flow cell at 280 nm or 494 nm. 
 
 SDS-PAGE and Western Blotting—Samples (100 µl) were collected from HPLC runs 
and analyzed by PAGE on 10% polyacrylamide SDS gels.  Proteins were transferred to 
nitrocellulose filters using a Semi-Dry Blotter (BioRad) in transfer buffer (0.35 M 
glycine, 25 mM Tris containing 20% (v/v) methanol).  Filters were blocked for non-
specific binding using 10% (w/v) nonfat dry milk at room temperature for 1 hour.  
Membranes were then washed three times after this and subsequent incubation steps with 
PBS containing 0.05% (v/v) Tween-20.  Immunoblotting was performed to detect 
vitronectin and PAI-1 simultaneously by incubating the filters with a 1:2,500 dilution of 
polyclonal anti-vitronectin rabbit serum and a monoclonal antibody raised against PAI-1.  
Antibodies were diluted in a 2.0% (w/v) solution of nonfat dry milk in PBS.  Blots were 
then probed using a 1:1,000 dilution of HRP-linked goat anti-rabbit and rabbit anti-mouse 
antibodies.  Immunostained protein bands were visualized by developing in a freshly 
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 prepared solution of 30 ml of PBS containing 50 mg/ml 4-chloronapthol and a 1:3,000 
dilution of 30% (v/v) hydrogen peroxide. 
 
 Fluorescence Measurements—Changes in the fluorescence emission of NBD-S119C-
PAI-1 were measured using a PerkinElmer LS50B luminescence spectrophotometer with 
an extinction wavelength of 480 nm and emission wavelength of 525 nm.  Excitation and 
emission slits were set at 4 and 7 mm, respectively.  Solutions of NBD-PAI-1 (200nM) in 
HEPES buffer (100 mM HEPES, 150 mM NaCl, 1 mM EDTA, 0.1% [w/v] polyethylene 
glycol-8000, pH 7.4) were titrated with small aliquots of vitronectin to a final 
concentration of 550 nM.  Samples were mixed in a total volume of 2.0 ml in acrylic 
cuvettes (Sarstedt) that were pre-treated with a 1.0% (w/v) solution of polyethylene 
glycol-20,000.  Titrations were performed in triplicate.   All data were mathematically 
corrected for dilution effects.  Change in emission was calculated using the equation (F-
Fo)/Fo, where F is the emission intensity and Fo is the starting emission intensity of NBD-
PAI-1 in the absence of vitronectin.  Emission scans were performed over a wavelength 
range of 500-600 nm using an excitation wavelength of 480 nm.  Measurements were 
plotted as a function of titrant concentration using the graphing KaleidaGraph (Synergy 
Software).  Data were fit to the Hill equation, 
(Eq.3-1)  
 
where S is the total titrant concentration, K0.5 corresponds to the titrant concentration at 
half-maximal saturation, and n is the Hill coefficient. 
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 Cell Binding Assays—Rabbit smooth muscle cells (gift from Dr. Dan Lawrence, 
American Red Cross) were grown to near confluence in tissue culture dishes in 
Dulbecco’s modified Eagle’s medium (DMEM).  Cells were harvested by trypsinization 
and subsequently incubated in DMEM containing 32P-labeled vitronectin with or without 
PAI-1.  Control cell binding experiments were also carried out using latent PAI-1.  
Mixtures were incubated at 37 ºC for 1 hour.  Following incubation, cells were 
centrifuged at 12,000 x g and resulting pellets were washed three times with PBS.  
Washed cell pellets were placed into a liquid scintillation mixture and measured for 
radioactivity in a Beckman LS3801 scintillation counter. 
 
 Matrix Binding Assays—96-well ELISA plates (polypropylene or polystyrene, CoStar) 
were coated with ECM (500 ng/well) or Matrigel (2.5 µg/well) in PBS.  Wells were 
washed three times with PBS and then blocked with 3.5% (w/v) BSA for 1 hour at 37 ºC.  
Vitronectin and PAI-1 were mixed in variable ratios in PBS containing 0.2% BSA and 
0.1% (v/v) Tween-20 (to prevent nonspecific binding), and samples were incubated for 
various times at 37 ºC.  Following washing with buffer containing BSA and Tween, 
vitronectin/PAI-1 mixtures (100 µl) were added and incubated at 37 ºC for 1 hour.  
Following incubations, mixtures were removed , wells washed, and bound vitronectin 
was detected by two different methods.  For ECM binding assays, detection was done 
using a polyclonal anti-vitronectin IgG and a peroxidase-conjugated anti-rabbit IgG.  
Plates were developed with a 0.2 mg/ml solution of ABTS in 50 mM sodium citrate, pH 
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 5.5, containing a 1:2,000 dilution of 30% hydrogen peroxide.  Detection was carried out 
in a Wallac Victor2 ELISA plate reader at a wavelength of 405 nm.  For the Matrigel 
binding assays, 32P-labeled vitronectin was used and bound protein was detected by 
scintillation counting.  Nonspecific binding was monitored in all experiments and found 
to be minimal.  Effects of nonspecific binding were subtracted from reported results.  
Assays described here were also performed to test the effects of ionic strength and tPA-
mediated release of PAI-1, using equimolar concentrations of tPA and PAI-1. 
 
 Integrin Binding Assays—ELISA plates were coated with 250 ng of GPIIbIIIa or αVβ3 
in Integrin-Binding Buffer (IBB, 50 mM Tris, pH 7.4, 150 mM NaCl, 1 mM MgCl2, 1 
mM CaCl2).  Wells were washed three times with IBB and then blocked with 3.5% (w/v) 
BSA for 1 hour at 37 ºC.  Equimolar or 1:2 (vitronectin:PAI-1) mixtures were incubated 
in IBB containing 0.2% BSA and 0.1% (v/v) Tween-20 for various times at 37 ºC.  
Following washing with IBB containing BSA and Tween, blocked wells were layered 
with vitronectin/PAI-1 mixures and incubated at 37 ºC for 1 hour.  Immunochemical 
detection of vitronectin was performed as described for the ECM binding assays.  Assays 
were also performed to test the effects of metals, ionic strength, and tPA-mediated release 
of PAI-1. 
 
Results 
 Size Exclusion HPLC Was Used to Monitor the Formation of Large Complexes 
Resulting from PAI-1 Binding to Vitronectin—For the purposes of the experiments 
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 described in this chapter, namely to investigate the effects of PAI-1-induced 
multimerization of vitronectin on cell-matrix binding, an HPLC method of size-exclusion 
chromatography was employed to monitor the formation of multimers.  Figure 2-1 shows 
chromatograms of equimolar mixtures of vitronectin and PAI-1 that were incubated for 
various times.  Separation immediately following mixing demonstrated the fast formation 
of very large complexes (elution time = 6 minutes).  From 1 to 4 hours, significant 
amounts of the high molecular weight complexes accumulated.  Analysis at long times 
(up to 36 hours) demonstrated that high molecular weight forms of vitronectin persisted, 
long after the disassociation of PAI-1 from the complex upon its conversion to a latent 
form. 
 In the HPLC experiments, NBD-S119C PAI-1 provided a chromophore to directly 
determine whether PAI-1 was an integral part of the high molecular complexes that form.  
As shown in Figure 2-2 (panel A), the elution profile at 494 nm (the extinction maximum 
for NBD) confirms that PAI-1 is present in the high molecular weight complexes formed 
after 1 hour.  Furthermore, SDS-PAGE and Western blotting (panel B) confirmed that 
these large complexes contained both vitronectin and PAI-1.  The same approach 
indicated that the high molecular weight species observed at long times (e.g. 36 hours) 
comprised oligomeric forms of vitronectin without associated PAI-1.  As a control, latent 
PAI-1 did not cause the formation of large complexes with vitronectin.  These results are 
in agreement with findings from earlier reports investigating the interaction between 
vitronectin and PAI-1 [119,127]. 
40
0
10
20
30
40
50
60
70
0 2 4 6 8 10 12 14
A
bs
or
ba
nc
e,
 2
80
 n
m
 (m
A
U
)
time, min
1 hr
4 hrs
15 hrs
36 hrs
0
10
20
30
40
50
60
70
0 2 4 6 8 10 12 14
0
10
20
30
40
50
60
70
0 2 4 6 8 10 12 14
0
10
20
30
40
50
60
70
0 2 4 6 8 10 12 14
Fig. 2-1. Size-exclusion HPLC evaluation of PAI-1-induced multimerization of 
vitronectin. Equimolar concentrations of vitronectin and PAI-1 were mixed and 
injected onto a Phenomenex size-exclusion column and chromatographed at a flow 
rate of 1 ml/min.  Reactions were carried out in PBS over several time points up to 36 
hours.  Samples were monitored at an absorbance of 280 nm.  Large complexes 
eluted from the column at the void volume elution time (time = 6 min).  Peak elution 
times measured for free vitronectin and free PAI-1 are 9.2 and 10.4 minutes, 
respectively.
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Fig. 2-2. PAI-1 is detected in high molecular weight vitronectin complexes.
Panel A depicts HPLC chromatograms for free NBD-S119C-PAI-1 (dashed line) and 
the labeled PAI-1 in complex with vitronectin (solid line) eluting from the size-
exclusion column at a flow rate of 1 ml/min.  Detection at 494 nm is specific for the 
NBD chromophore.  Note the presence of PAI-1 in complexes that elute at the void 
volume (time = 6 minutes).  Panel B shows SDS-PAGE and Western blotting to 
confirm the presence of PAI-1 in the early eluting peaks fom the HPLC column.  
Small volume (100 µl) fractions were collected at the elution times indicated by the 
bar in panel A.  These samples were run on a 10% polyacrylamide gel and transferred 
to nitrocellulose for Western blotting analysis using anti-vitronectin and anti-PAI-1 
antibodies concurrently.  The far left lane on the gel, labeled Control Proteins, 
contains purified vitronectin and PAI-1 that were combined in equal concentrations, 
mixed with SDS-PAGE loading dye, and boiled for loading and electrophoresis.  
Also shown in the far right lane are prestained molecular size standards.
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  The information obtained from this HPLC gel filtration approach was instructive for the 
remainder of the study described here.  By monitoring the formation of complexes 
between vitronectin and PAI-1 over time, we could correlate this information with effects 
of PAI-1-induced multimerization on the adhesive properties of vitronectin.  We were 
especially interested in functions relative to matrix and/or cellular interactions. 
 
 PAI-1 Effects on Vitronectin Enhance Its Interaction with Extracellular Matrices—
Research from this laboratory [118], which demonstrates the positive effect of increased 
valency (upon vitronectin multimerization) on the binding of vitronectin to heparin, raises 
the possibility that PAI-1-induced oligomerization of vitronectin may also enhance the 
binding of the protein to other ligands.  Of particular interest is the association of 
vitronectin and its complexes with the ECM, which will be enhanced by interactions with 
the multivalent substrates in the matrix and which may be mediated by heparin-like 
glycosaminoglycans.  The ability of vitronectin to interact with both integrins and matrix 
proteins places vitronectin at the boundary of cell-matrix interactions and activities.  
Results presented in Figure 2-3 address this idea by demonstrating that vitronectin, when 
incubated with PAI-1, shows increased binding to matrix-coated ELISA plates.  The 
enhanced binding of vitronectin upon incubation with PAI-1 was demonstrated using two 
commercially available matrices, human ECM and Matrigel.  Binding of complexes is 
observed with both types of matrix and is detected using either immunochemical (panel 
A) or radiological (panel B) detection, indicating a specific effect of PAI-1 on matrix 
incorporation of vitronectin.  These findings support a model in which PAI-1 promotes 
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Fig. 2-3. Complexes of vitronectin and PAI-1 associate with the ECM. The 
effects of PAI-1 binding on the adhesive properties of vitronectin were measured 
using human ECM-coated ELISA plates (panel A) or Matrigel-coated plates (panel 
B) as described in Material and Methods.  Equimolar concentrations of vitronectin
and active PAI-1 were mixed and incubated for 1 hour prior to addition to matrix-
coated wells.  Binding of varying concentrations of vitronectin (○) or 
vitronectin/PAI-1 complexes (●) was detected using a polyclonal antibody against 
vitronectin (panel A) or by scintillation counting (panel B). Error bars represent 
standard errors.
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 the formation of vitronectin oligomers that display enhanced affinity for components that 
constitute the ECM. 
 Although equimolar mixtures of vitronectin and PAI-1 exhibited enhanced association 
with the ECM, as shown in Figure 2-3, we considered whether non-stoichiometric 
mixtures of the two proteins would vary in matrix-binding behavior.  This experiment 
was initiated in light of published results from this laboratory that demonstrate the 
association of vitronectin and PAI-1 into complexes with a 2:4 (vitronectin:PAI-1) 
stoichiometry [127].  Thus, the concentration of vitronectin was fixed in the ECM-
binding assays, whereas the concentration of PAI-1 was varied from less than 
stoichiometric to a 4-fold excess relative to vitronectin.  As shown in Figure 2-4, matrix 
binding is dependent on the amount of PAI-1 present, saturating at a higher value for 
relative binding than that observed for the 1:1 ratio kept constant in Figure 2-3.  For this 
reason, subsequent ECM-binding experiments were performed using a 2:1 ratio of PAI-
1:vitronectin, and these results show a greater enhancement in ECM binding than the 
titrations shown in Figure 2-3.  Latent PAI-1, tested over a wide range in concentrations, 
had no effect on matrix binding by vitronectin. 
 
 The Time Course of PAI-1-Induced Multimerization of Vitronectin Parallels 
Enhanced Association with the ECM—To correlate the observed effects of PAI-1 
binding on vitronectin adhesive functions and the formation of large multimeric 
complexes as a result of this interaction, these properties were carefully monitored over 
time.  Mixtures of vitronectin and PAI-1 were incubated for various times and then added 
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Fig. 2-4. Vitronectin deposition into the ECM is dependent on PAI-1 binding.
Enhanced binding of vitronectin to the ECM was shown to vary with the amount of 
PAI-1 in a saturable fashion using ECM-coated ELISA plates as described in 
Materials and Methods.  Increasing concentrations of active (▲) or latent (○) PAI-1 
were mixed with a fixed concentration (20 nM) of vitronectin and incubated for 1 
hour prior to addition to ECM-coated wells.  Binding of the complexes to the matrix 
is detected using a polyclonal antibody to vitronectin and a peroxidase-labeled 
secondary antibody acting on ABTS.  Product in the ELISA is detected by 
absorbance at 405 nm.  Results are expressed as the increase in binding relative to 
the binding of vitronectin in the absence of PAI-1.  Error bars represent standard 
errors.
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 to ECM-coated ELISA plates.  Figure 2-5 (panel A) demonstrates the significant increase 
in the amount of vitronectin bound to matrix when PAI-1 is added versus native 
vitronectin alone.  Strikingly, this increase in matrix deposition persists at long times 
after which PAI-1 is no longer present in the large complexes.  These results indicate that 
PAI-1 binding causes a consistent enhancement of the adhesive form of vitronectin in a 
temporal pattern similar to that of complex formation and vitronectin multimerization 
observed in the HPLC time course described above. 
 To explicitly test whether PAI-1 is required as a component in the higher-order 
complexes for the enhancement in binding to the matrix, tPA was added to the incubation 
mixtures at timed intervals.  This serine protease plays an important role in fibrinolysis, 
where it directly converts plasminogen into the proteolytically-active plasmin.  Plasmin is 
important in breaking down fibrin clots and extracelluar remodeling.  TPA attacks the 
pseudo-substrate RCL on PAI-1, and inhibition occurs as PAI-1 forms a  stable acyl-
complex.  It has been shown that when tPA acts on PAI-1 bound to vitronectin, the 
vitronectin/PAI-1 interaction is disrupted and the tPA/PAI-1 complex is irreversibly 
released [Lawrence, 1997 #174].  Dissociation of the vitronectin/PAI-1 complex by 
adding tPA at early times (~1 hour) diminishes binding to the matrix, as shown in Figure 
2-5 (panel A).  Note that the binding observed is nevertheless enhanced relative to the 
binding of monomeric vitronectin.  Indeed, analysis by HPLC gel filtration (Figure 2-5 
panel B) demonstrated that by 1 hour, a stable multimeric form of vitronectin that more 
readily associates with the matrix is present, and that it persists even after tPA-mediated 
release of PAI-1.  The fact that tPA treatment reduces the amount of complexes observed 
47
010
20
30
40
50
60
0 5 10 15 20 25 30 35 40
A
bs
or
ba
nc
e,
 2
80
 n
m
 (m
U
)
Elution time, min
B
0
1
2
3
4
5
6
7
vitronectin 1 hour 3 hrs 9 hrs 24 hrs
Re
la
tiv
e 
Bi
nd
in
g
A
Fig. 2-5. Evaluation of the effects of multimerization of vitronectin on binding 
to the ECM using tPA to neutralize PAI-1.  Panel A, samples of vitronectin with or 
without active or latent PAI-1 were incubated for various times at 37 ºC and then 
tested for binding to ECM-coated ELISA plates as described in Materials and 
Methods.  Results are expressed relative to the observed binding of free monomeric
vitronectin to the ECM, normalized to a value of 1.  The solid bar represents the 
binding of monomeric vitronectin to the plates, a value that remains unchanged over 
the time course of the experiment.  Open bars represent the binding of 
vitronectin/PAI-1 complexes, whereas shaded bars represent binding of mixtures 
treated with tPA.  Error bars represent standard errors.  Panel B, the effects of 
dissociation of PAI-1 from vitronectin complexes were evaluated by size-exclusion 
HPLC.  Chromatograms corresponding to vitronectin alone (dotted line), equimolar
mixtures of vitronectin and PAI-1 incubated for 1 hour (dashed line), and mixtures of 
vitronectin and PAI-1 incubated for 1 hour followed by treatment with tPA (solid 
line), are shown.
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 indicates that active PAI-1 is present in these high molecular weight complexes formed at 
1 hour.  From the decrease in peak height eluting at the void volume of the column, the 
findings also indicate that some of the complexes can disaggregate when tPA neutralizes 
PAI-1.  However, at longer times, adding tPA to the mixtures has little effect, indicating 
that the aged vitronectin aggregates exhibit enhanced matrix binding that is independent 
of PAI-1.  This is an interesting finding that suggests that at early time points, the 
vitronectin/PAI-1 complex relies heavily on the presence of PAI-1 for stability and 
functionality.  However, as the complexes assemble further along the time scale, PAI-1 
becomes less important, indicating that stable contacts between self-associating forms of 
vitronectin have formed.  
 
 Enhancement of Binding of Vitronectin/PAI-1 Complexes to ECM is Dependent on 
Ionic Strength—As shown in Figure 2-6, increasing ionic strength can reverse the 
association of vitronectin complexes with the matrix upon PAI-1 binding.  At a 1 M NaCl 
concentration, the enhancement of vitronectin binding is decreased by ~70%.  These 
results indicate that the binding of vitronectin/PAI-1 complexes to components of the 
ECM is presumably mediated through ionic interactions like those that are known to 
occur between vitronectin and glycosaminoglycans. 
 To ensure that these results are not because of an effect of ionic strength on the 
interaction between PAI-1 and vitronectin, the binding of PAI-1 and vitronectin was 
monitored at varying ionic strengths using a fluorescence-based assay with PAI-1 labeled 
with the environmentally-sensitive fluorophore NBD (N,N’-dimethyl-N-(acetyl)-N’-(7-
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Fig. 2-6. Effects of increase ionic strength on PAI-1-mediated binding of 
vitronectin to ECM. Vitronectin and active PAI-1 were mixed in a 2:1 ratio and 
incubated for 1 hour prior to addition to ECM-coated wells.  The samples were added 
to buffer of varying ionic strength for incubation with the matrices in wells.  Results 
are expressed as percentage of binding relative to samples in PBS taken as 100%.
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 nitrobenz-2-oxa-1,3-diazol-4-yl)ethylenediamine).  As PAI-1 has no cysteine residues in 
its wild-type form, site-directed mutagenesis to engineer in cysteines at chosen sites 
offers a valuable tool for labeling PAI-1 with reporter probes in strategic locations, like 
those that can be used to signal a ligand-binding event.  Here, a serine-to-cysteine 
mutation at residue 119 that was engineered into the wild-type backbone of PAI-1 was 
labeled with NBD, where the placement of NBD is within the vitronectin-binding site of 
PAI-1. Using NBD-labeled PAI-1, an equilibrium titration experiment was carried out by 
adding in increasing amounts of vitronectin to a constant concentration of PAI-1 and 
monitoring the changes in fluorescence intensity as a function of vitronectin 
concentration.   Binding of native, monomeric vitronectin to the NBD-labeled PAI-1 
resulted in a 50% enhancement in fluorescence intensity compared to labeled protein 
alone.  This enhancement is indicative of vitronectin binding, as this event results in a 
shift of the NBD probe on PAI-1 into more hydrophobic surroundings, i.e. the 
vitronectin/PAI-1 binding interface. 
 Binding isotherms for NBD-S119C-PAI-1 and vitronectin, in the presence of both 150 
and 500 mM NaCl, are shown in Figure 2-7, titration of NBD-labeled PAI-1 with 
vitronectin resulted in a binding isotherm that has a sigmoid shape.  Allosteric binding 
isotherms were observed, reflecting a complex association phenomenon consistent with 
analytical ultracentrifugation studies that demonstrate a non-stoichiometric binding of 
PAI-1 and vitronectin accompanied by self-association of vitronectin [127].  Under both 
ionic strengths, a K0.5 of ~60 nM and a Hill coefficient of 2.2 were obtained.  Differences 
observed in the maximal fluorescence change observed with the two salt concentrations 
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Fig. 2-7. Fluorescence experiments using NBD-labled PAI-1 demonstrate that 
PAI-1-binding to vitronectin is not influenced by ionic strength. Small volume 
aliquots of monomeric vitronectin were added to a 2-ml sample of NBD-labeled 
S119C-PAI-1 at a final concentration of 0.2 µM.  Binding was measured by 
monitoring the increase in the fluorescence emission of NBD (emission at 525 nm) 
upon vitronectin binding to PAI-1.  Experiments were performed at NaCl
concentrations of 0.15 M (open circles) and 0.50 M (solid circles).   Smooth curves
show fits to the Hill equation.
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 are presumably because of intrinsic properties (e.g. quantum yield, exposure to solvent, 
quenching ) of the fluorophore at the tow ionic strengths.  Salt-dependent quenches of 
fluorescence are a well-established phenomenon in photobiophysics [128].  These 
findings demonstrate that similar complexes form between PAI-1 and vitronectin 
regardless of the ionic strength of the solution environment.  Furthermore, they argue that 
the ionic-strength dependent effects observed in Figure 2-6 reflect dissociation of the 
complexes from the ECM rather than dissociation of PAI-1 from vitronectin.   
 
 Multimerization Promoted by PAI-1 Binding Enhances the Interaction of Vitronectin 
with Cell Surface Receptors—If vitronectin/PAI-1 complexes have a propensity to 
become matrix-associated, a plausible corollary is that adhesive properties of the 
complexes will be affected.  To test the effects on adhesive properties of vitronectin that 
may be affected upon PAI-1 binding, we applied a cell-binding assay using rabbit smooth 
muscle cells (SMCs) and radiolabeled vitronectin.  Incubation of vitronectin with PAI-1 
resulted in an increase in the amount of vitronectin that adhered to SMCs (Figure 2-8).  
Although active PAI-1 caused a nearly 2-fold increase in vitronectin binding to SMCs, 
latent PAI-1 did not have any effect.  These findings coupled with the HPLC  results 
described above indicate that PAI-1 binding to vitronectin results in the formation of 
large complexes that are more adhesive to cell surfaces than the monomeric (circulating) 
form of vitronectin. 
 To further investigate the effects of PAI-1 binding on adhesive properties of vitronectin 
to cells, a solid-phase binding assay using purified integrins was employed.  Similar to 
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Fig. 2-8.  PAI-1 enhances the binding of radiolabeled vitronectin to smooth 
muscle cells. Rabbit smooth muscle cells were incubated 32P-vitronectin with or 
without PAI-1.  Control cell binding experiments also were conducted using latent 
PAI-1.  Protein-cell mixtures were incubated at 37 °C for 1 hour followed by 
centrifugation at 12,000 x g to pellet cells.  Cell pellets were washed with PBS and 
measured for radioactivity in a Beckman LS3801 scintillation counter.
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 the binding to SMCs, vitronectin showed an increased binding to GPIIbIIIa- or αVβ3-
coated ELISA plates when incubated with active PAI-1 (Figure 2-9, panels A and B).  
Over a wide range of concentrations, a consistent enhancement of vitronectin binding 
was observed; this finding was apparent at concentrations as low as 10 nM vitronectin 
and PAI-1.  The binding was saturable with respect to vitronectin (panel A) or PAI-1 
(panel B).  This effect was not observed with latent PAI-1 (panel A).  Ratios of PAI-1 to 
vitronectin that exceed 1:1 give maximal binding to integrins, presumable reflecting the 
nonstoichiometric association of the two proteins [127].  These observations give further 
evidence that PAI-1-induced multimerization of vitronectin is correlated with 
enhancement in binding to cell surfaces. 
 A cursory evaluation of the mechanism by which PAI-1 enhances the association with 
integrins as described above involved experiments that measured several properties 
inherent to integrins and PAI-1 as partners with vitronectin in the binding phenomena.  
Integrin binding to ligands occurs through a variety of mechanisms, some of which 
involve metal-dependent interactions.  Quite strikingly, the binding of vitronectin/PAI-1 
complexes to GPIIbIIIa is abolished in the presence of EDTA (Figure 2-10).  Binding of 
uncomplexed vitronectin to the receptor was also diminished in the presence of EDTA.  
Additionally, ionic strength dependence was observed for vitronectin binding to 
GPIIbIIIa.  Binding of the vitronectin/PAI-1 complexes was diminished significantly 
when measured in the presence of 0.5 and 1.0 M NaCl, respectively.  Furthermore, 
binding of the complexes to the receptors was reduced when tPA was added and the 
serpin-protease complexes dissociate from vitronectin.  As shown in Figure 2-10, this 
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Fig. 2-9. PAI-1-induced multimerization enhances the binding of vitronectin to 
GPIIbIIIa. Panel A, vitronectin was pre-incubated with an equimolar amount of 
active PAI-1 (●) or with integrin-binding buffer alone (○) for 1 hour at 37 ºC.  A 
control using a high concentration a high concentration of latent PAI-1 is shown (▲).  
These solutions were then incubated with GPIIbIIIa-coated ELISA wells as described 
in Materials and Methods.  Following a 1-hour incubation at 37 ºC, wells were 
washed and bound vitronectin was detected using an anti-vitronectin IgG.  Results 
are given in absorbance units at 405 nm.  Panel B, varying concentrations of PAI-1 
were mixed with a fixed concentration of vitronectin (20 nM) and pre-incubated for 1 
hour at 37 ºC.  Protein samples were then incubated for 1 hour with GPIIbIIIa-coated 
(○) or αVβ3-coated (▲) ELISA wells as described in Materials and Methods.  Bound 
vitronectin was detected again by an anti-vitronectin IgG.  Results are expressed as 
an increase relative to the binding of vitronectin in the absence of PAI-1.
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Fig. 2-10. Effects of EDTA, ionic strength, and addition of tPA on PAI-1-
mediated binding of vitronectin to GPIIbIIIa. Vitronectin and active PAI-1 were 
mixed in a 2:1 ratio and incubated for various times prior to addition to integrin-
coated wells.  The binding of both monomeric and PAI-1-complexed vitronectin to 
GPIIbIIIa were measured in the presence and absence of 10 mM EDTA.  Also shown 
are the effects of varied ionic strength and addition of tPA on the binding of 
vitronectin/PAI-1 to GPIIbIIIa.  Results are expressed as the relative binding 
compared with that of untreated monomeric vitronectin with integrin-coated wells 
(value normalized to 1).  Error bars represent standard errors. 
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 effect is notable at 1 hour in experiments evaluating association with GPIIbIIIa.  In fact, 
the dependence of integrin binding on the presence of PAI-1 in the complexes at the 1-
hour time point is more pronounced than was observed in the matrix binding experiments 
(Figure 2-5 panel A).  However, these effects are minimized at longer times with both 
integrins (data not shown) and matrices (Figure 2-5 panel A) when latent PAI-1 
accumulates and oligomeric vitronectin prevails. 
 
Discussion 
 Proper cell adhesion and migration is required for the maintenance of homeostasis; 
alterations in these processes can lead to pathological situations such as impaired blood 
clotting and wound healing.  In addition, tumor cells can modify their own adhesive 
properties and acquire the ability to exit residing tissues and travel to other sites and 
metastasize.  Investigation into both normal and pathological processes related to cell 
adhesion and migration represents an important area of clinical research and a focus of 
this work.  The study presented here considers vitronectin and PAI-1, and the potential 
roles they may play in cellular adhesion, specifically through the ability of PAI-1 to 
induce the transition of vitronectin to a multivalent form. 
 Both PAI-1 and vitronectin have been widely studied as regulators of cellular adhesion.  
As discussed in Chapter 1, vitronectin has also been shown to localize to focal adhesion 
sites and promote cell spreading and migration through its ability to interact with cell 
surface proteins like uPA receptor and integrins [41].  Most of the previous work with 
PAI-1 has focused on a steric interference with integrin binding to vitronectin because of 
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 the juxtaposition of a primary PAI-1-binding site and the RGD motif near the N-terminal 
end [135-137]. 
 The studies discussed in this dissertation take a different perspective and aim to 
investigate the role that PAI-1 plays in promoting self-association of vitronectin and what 
effects it will have on the incorporation of complexes into the ECM displaying adhesive 
properties.  The hypothesis tested here suggests that PAI-1 represents a physiological 
cofactor for the conversion of vitronectin into its matrix-associated (multimeric) form.  
Several lines of evidence demonstrate that PAI-1 can induce vitronectin multimerization 
through the formation of large higher-order complexes.  Seiffert and Loskutoff were the 
first to demonstrate that vitronectin formed large complexes upon binding to PAI-1, and 
that these complexes were stable long after the disassociation of PAI-1 [119].  This study 
also demonstrated that binding of PAI-1 and subsequent formation of vitronectin 
multimers resulted in increased binding of vitronectin to conformationally-sensitive 
antibodies and to heparin.  Analytical ultracentrifugation approaches have offered an in-
depth study regarding complexes of PAI-1 and vitronectin (here in Chapter 4, and [127]), 
with the demonstration that an early event in the pathway leading to vitronectin self-
association is the formation of intermediate complexes consisting of a 4:2 ratio of PAI-1 
to vitronectin.  Over time, these complexes convert to stable vitronectin oligomers with 
the conversion of PAI-1 to the inactive form. 
 It can be postulated that these intermediate vitronectin/PAI-1 complexes may serve to 
couple functions of vitronectin in cellular adhesion with functions of PAI-1 in regulating 
matrix degradation.  Studies were designed to ask the following questions:  Does 
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 multimerization of vitronectin, as a consequence of PAI-1 binding, result in enhanced 
binding to integrins and components of the ECM?  Does PAI-1 binding lead to a 
“clustering” of binding sites for these ligands such that vitronectin becomes 
“activated” into a multivalent, adhesive form?  What types of interactions mediate the 
interaction of PAI-1/vitronectin complexes with integrins and the ECM?  How does the 
temporal assembly of higher-order PAI-1/vitronectin complexes correlate with the 
adhesive nature of vitronectin?   A set of experiments were designed to follow the 
multimerization event and correlate this with the association of vitronectin/PAI-1 
complexes with cellular and matrix components in a solid-phase platform. 
 A time course was evaluated to monitor the formation of complexes between 
vitronectin and PAI-1, extending to times sufficient to allow for the release of latent PAI-
1.  This method demonstrated the immediate formation of large complexes containing 
vitronectin and PAI-1, leading to observable vitronectin multimers after PAI-1 release.  
The picture that emerged correlated well with results from both matrix- and cell-binding 
studies, in that an enhancement in vitronectin binding to both ligands was associated with 
complex formation between vitronectin and PAI-1.  Comparing the HPLC time course 
with a ligand-binding time course using ECM demonstrates a nice correlation between 
augmentation of binding and formation of higher-order species.  In addition, it is evident 
that this enhancement of binding of vitronectin to the ECM is observable long after the 
release of PAI-1, indicating that the effect is because of the conversion of vitronectin into 
large multivalent species. 
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  A scheme shown in Figure 2-11 [128] helps in considering the dynamic processes that 
occur in the vitronectin/PAI-1 interaction over a fairly long time scale up to 24-36 hours.  
At all times after mixing of the two proteins, there are assembly and disassembly 
processes that occur simultaneously.  Immediately after mixing, PAI-1 binds to 
vitronectin and promotes the formation of higher-order complexes.  When tPA is added 
to the mixture, it binds to and neutralizes PAI-1, thus releasing it from vitronectin, and 
yields a mixture of species including vitronectin multimers and dissociated monomers.  
At extremely long times (e.g. 24 hours), all PAI-1 has converted to a latent form and is no 
longer bound to vitronectin multimers, and therefore the addition of tPA has essentially 
no effect.  At intermediate times, represented by the 3-hour time point in Figure 2-11, 
there are competing processes in which latent PAI-1 accumulates and tPA has less of an 
effect in binding active PAI-1 and removing it from vitronectin complexes.  These 
competing processes explain in part the curious observation at 3 hours that tPA has little 
effect on the association of vitronectin multimers with the ECM. 
 The findings presented in this study demonstrate the effects of PAI-1-induced 
multimerization on the adhesive properties of vitronectin by correlating binding to cells, 
integrins, and matrix proteins.  Variations in the adhesive properties of monomeric and 
self-associated forms of vitronectin induced by PAI-1 are reminiscent of earlier studies 
demonstrating the altered effects of chemically-induced multimerization of vitronectin on 
binding to cell surfaces and ECM components [47,61,65,118,129].  An important 
example of this involves binding to the polyvalent ligand, heparin, with the artificially-
denatured, also polyvalent form of vitronectin that is responsible for an apparent 
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Fig. 2-11. A model for association of vitronectin into complexes with altered 
adhesive properties. This schematic illustrates the assembly of vitronectin/PAI-1 
complexes, their association into higher-order multimers, and dissociation of latent 
PAI-1 over time, and the neutralization of PAI-1 by tPA.  Vitronectin is depicted as 
blue ovals; PAI-1 by yellow ovals; and tPA by red ovals.  Immediately upon mixing, 
vitronectin and PAI-1 form higher-order oligomers that build upon complexes with a 
1:2 vitronectin:PAI-1 stoichiometry.  Within 1 hour of mixing, a considerable 
amount of multimers have formed.  Addition of tPA dissociates PAI-1 from 
vitronectin and yields both stable vitronectin oligomers and dissociated monomers.  
At extremely long times (e.g. 24 hours), all PAI-1 has converted to a latent form and 
is no longer bound to vitronectin multimers, and as such tPA has little effect on 
remaining complexes.  During this time course, multimeric adhesive complexes of 
vitronectin form in increasing amounts until a maximal level is reached.
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 enhancement in binding that is attributed to changes in the stoichometry of binding rather 
that to changes in the affinity for heparin binding [118].  In a similar fashion, changes in 
the binding of vitronectin to matrix ligands such as glycosaminoglycans presumably 
result from a conversion of vitronectin into a multivalent state. 
 As discussed in Chapter 1, several studies have demonstrated that PAI-1 can also 
inhibit vitronectin binding to cell-surface receptors [135-139].  Although these 
observations would seem at odds with the demonstration in this study of enhanced cell or 
matrix binding in PAI-1-induced multimers, a careful consideration reveals that the 
experiments cannot be easily compared.  Indeed, the former studies used vitronectin 
already in a chemically-induced (or plastic-coated) multimeric form, and therefore do not 
evaluate the effects of complex formation followed by multimerization of 
vitronectin/PAI-1.  These studies, although informative, do not accurately reflect the 
physiological events that can occur between vitronectin and PAI-1 in vivo.  In contrast, 
the approach of the studies described here are more physiological in nature, and lead to 
the conclusion that PAI-1 is a physiological cofactor that can regulate the tissue 
distribution and adhesive functions of vitronectin. 
 Immunohistological studies give evidence that vitronectin and PAI-1 become co-
localized at sites of tissue injury and disease [102,111,123-126].  This chapter presents 
the first support that these findings reflect the deposition of vitronectin/PAI-1 complexes 
into tissues that result in local remodeling of the ECM linked to injury, necrosis, and 
cancer.  It is clear that investigation into the role of ligand-induced multimerization of 
vitronectin is physiologically significant and demands attention.  In light of this, we 
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 decided to study the role of PAI-1-induced multimerization of vitronectin in a living 
human fibroblast system, and the results of this study are summarized in the following 
chapter.   
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CHAPTER 3 
 
PLASMINOGEN ACTIVATOR INHIBITOR-1 PROMOTES THE 
RELOCALIZATION OF VITRONECTIN TO THE 
EXTRACELLULAR MATRIX* 
 
 
 
*This chapter is a revised version of a manuscript under the same title that has been 
submitted for publication in Biochemica et Biophysia Acta in 2005 by Kenneth H. Minor, 
Cynthia E. Wilkins-Port, Christine R. Schar, , Srilalitha Kuruganti, Paula J. McKeown-
Longo, and Cynthia B. Peterson [140]. 
 
My contributions to this paper include: (1) aiding in the development and design of 
experimental goals and procedures, (2) performing most experiments and collections of 
data, (3) analyzing collected data, (4) designing how the results were illustrated, and (5) 
writing the manuscript in collaboration with my mentor Dr. Cynthia Peterson. 
 
Introduction 
 The findings described in Chapter 2 support a model in which binding to PAI-1 leads 
to the structural conversion of vitronectin into a matrix-associating, activated form that in 
turn displays altered adhesive properties [128].  This conversion involves the 
multimerization of vitronectin to an adhesive form that is similar to one that develops 
upon chemical denaturation, a form that also displays differences in cell/matrix adhesion 
when compared to the circulating, monomeric form [47,65,129,130,141].   As discussed 
in Chapter 1, vitronectin contains binding sites for cell-surface receptors including 
integrins [31,46,60,65,130,136,137,141], syndecan  and uPAR [60,142]; it also harbors 
sites specific for components of the ECM, including collagen [36,37,52,143] and GAGs 
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 [47,117,144,145].  This property of vitronectin endows the protein with the unique ability 
to couple functions related to both cell adhesion and matrix binding. 
 The premise underlying this study is that multimeric vitronectin found within tissues 
is produced by physiological stimuli, in particular through the interaction of circulating 
vitronectin with biological ligands such as PAI-1.  Several studies have identified 
structural modifications in vitronectin that result from the interaction with PAI-1 
[119,128].  In Chapter 2, a series of experiments are presented that show evidence that 
PAI-1 binding to vitronectin leads to the formation of higher-order complexes that exhibit 
altered binding to cellular integrins and the ECM in isolated systems using purified 
components [127,128].  It is proposed that elevated PAI-1 levels, which are correlated 
with physiological stress following injury or during cancer progression, promote 
conversion of plasma vitronectin to an altered, multimeric form that becomes deposited 
onto the ECM.  At that locus, the protein assumes its role in promoting cell adhesion 
and/or matrix remodeling.   
 In the following studies, this hypothesis is tested for the first time in cell culture. 
Does PAI-1-induced multimerization associated with increased deposition of 
vitronectin in the ECM?  Does this event result in an increase in binding of vitronectin 
to cell-surface receptors? What cell-surface receptors and matrix components are 
involved?   Does PAI-1 co-localize with vitronectin at the cell-matrix interface?  The 
importance of PAI-1 binding to vitronectin leading to structural and functional changes 
manifested by cellular uptake and deposition in the ECM are addressed using cultured 
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 fibroblasts treated with the circulating form of vitronectin or with PAI-1/vitronectin 
complexes.   
  
 
Materials and Methods 
 Proteins and Antibodies—Vitronectin was isolated from human plasma using a 
purification strategy described previously [146,147], which is a modified procedure 
designed by Dahlback and Podack [134].  Recombinant wild-type PAI-1, stable mutant 
PAI-1 (14-1B), tPA, and monoclonal anti-PAI-1 antibody were obtained from Molecular 
Innovations, Inc.  Monoclonal antibody against αvβ5 was purchased from Chemicon.  
Fluorescently labeled secondary antibodies (anti-rabbit and anti-mouse IgG) used in 
immunostaining came from Molecular Probes, Inc., as well as biotinylation kit used for 
labeling vitronectin.  RGDS peptide was purchased from Sigma.  All cell culture 
materials were obtained from ATCC.  
 
 Cell Culture—Human foreskin fibroblasts (A1-F) were a gift from Dr. Lynn Allen-
Hoffman (University of Wisconsin, Madison, WI).  Cells were maintained in Dulbecco’s 
Minimal Essential Medium (DMEM) supplemented with 10% fetal bovine serum (FBS).  
For experiments, confluent cells grown in T75 flasks were removed by treatment with 
trypsin, and re-seeded onto 24-well cell-culture plates or multi-chamber glass microscope 
slides. 
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  Iodination of Vitronectin—Vitronectin was iodinated by incubating native protein 
(200 µg) with 0.5 mCi Na125I in the presence of lactoperoxidase (10 µg/ml), glucose 
oxidase (1 U/ml), and glucose (40 mM).  The reaction was carried out for 5 minutes and 
then stopped by adding bromophenol blue and 10 mg/ml tyrosine.  Free iodine was 
removed by size-exclusion chromatography using a G-25 Sephadex filtration column.  
Radiolabeled vitronectin was stabilized with 0.1% phenylmethyl sulfonyl fluoride-treated 
bovine serum albumin (BSA) and dialyzed against phosphate buffered saline (PBS).  
Aliquots of vitronectin were stored at -70°C until use.  Integrity of native vitronectin was 
checked by SDS-PAGE and autoradiography.  Specific activity was approximately 1 
µCi/µg protein. 
 
 Binding and Degradation of Vitronectin—Experiments were carried out as 
previously described [129,148].  For binding studies, ascorbate-treated A1-F fibroblasts 
were grown as confluent monolayers in 24-well plates and incubated with 125I-labeled 
vitronectin in either the native conformation or in the multimeric form as induced by 
active human PAI-1.  Multimeric vitronectin complexes were generated by incubating 
vitronectin and PAI-1 at varying stoichiometric ratios in DMEM at 37°C for 30 minutes.  
Added vitronectin (final concentration 2.5 µg/ml) was incubated with fibroblasts for 5 
hours at 4°C to prevent internalization and degradation so to measure binding to the 
monolayer solely.  Following incubation, radioactive medium was removed and cell 
layers were washed several times with ice-cold PBS to remove non-bound vitronectin.  
Cell layers were solubilized in 1 N NaOH and radioactivity was measured by gamma 
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 counting.  Bound vitronectin was determined to be the percent of 125I-vitronectin that 
remained associated with the cell layer.  As indicated, binding experiments were also 
carried out to evaluate the effects of tPA-mediated release of PAI-1 from oligomeric 
complexes. 
 Degradation experiments were carried out as above except that cultures were 
incubated at 37°C.  Vitronectin degradation was determined by measuring the level of 
trichloroacetic acid (TCA) (10% final concentration) soluble radioactivity present in the 
medium following a 5 hr incubation with 125I-labeled vitronectin.  Background 
degradation was determined in parallel wells with DMEM and 10% FBS in the absence 
of cells.  Percent degradation was calculated by subtracting background radioactivity, and 
dividing by the total amount of 125I-vitronectin added to each well.  For each degradation 
sample, the amount of vitronectin bound to the cell layer was also determined by washing 
cells and measuring radioactivity in solubilized monolayers.   
        
 Immunofluorescence Microscopy—Vitronectin was labeled (kit from Molecular 
Probes, Inc.) on primary amines with biotin so that exogenously added protein could be 
differentiated from that from cultured serum.  Fibroblasts were cultured on glass 
microscope slides with attached multi-well chambers.  DMEM medium was added to 
cells, including medium containing biotinylated vitronectin in both native and PAI-1-
induced multimeric forms.  The final concentration of vitronectin was 25 µg/ml and in 
formation of multimeric complexes, PAI-1 was pre-incubated with vitronectin for 30 
minutes at a 1:1 molar ratio.  Vitronectin-containing medium was added to cells and 
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 incubated at 37°C for 30 minutes to allow time for internalization.  To prevent lysosomal 
degradation, cultures were treated with medium containing chloroquine.  At the end of 
incubation, cells were washed three times with PBS and then fixed using 3.7% 
paraformaldehyde (30 minute treatment at 37°C).  Fixed cells were permeablized for 10 
minutes at 4°C with cold buffer containing 0.5% Triton X-100, and then blocked with 
PBS containing 3.5% BSA for 1 hr at room temperature.  Anti-PAI-1 IgG (1:1000) and 
fluorescein isothiocyanate (FITC)-conjugated streptavidin (to detect biotinylated 
vitronectin) were added in PBS containing 1% BSA.  Primary detections were carried out 
for 1 hour at room temperature, followed by several washes using PBS.  PAI-1 was 
detected with AlexaFluor 568-tagged goat anti-mouse IgG by incubating for 1 hour at 
room temperature.  Following final washes in PBS, cover slips were added using anti-
fade mounting media.  Staining was observed with an Olympus epifluorescence 
microscope and images were captured and transferred to Adobe Photoshop with a 
Hamamatsu color 3CCD camera.  Confocal imaging was performed using a Leica TC 
SP2 laser-scanning confocal microscope. 
  
 Isolation of ECM from Fibroblast Monolayers—Cells were grown to confluence on 
glass microscope slides and carefully removed from ECM using 0.02 M ammonium 
hydroxide treatment for 10 minutes.  Isolated matrices were washed 3 times using PBS 
and slides were blocked with 3.5% BSA.  Following blocking, biotinylated vitronectin 
and PAI-1/vitronectin complexes were added to matrices in PBS and incubated for 1 hour 
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 at 37°C.  Immunostaining of vitronectin and immunofluorescence microscopy was 
carried out as described above.  
  
 
Results 
 PAI-1 Binding Promotes Increased Processing of Vitronectin by Human A1-F 
Fibroblasts—Results presented in Chapter 2 provide evidence that PAI-1 binding to 
vitronectin induces formation of multivalent complexes that display altered binding to 
purified cell-surface receptors and ECM components [128].  To determine if these effects 
are observed in living cellular models, experiments were conducted to evaluate the 
effects of PAI-1/vitronectin complex formation using human foreskin fibroblasts (A1-F) 
grown as cell-matrix monolayers.  Experimental procedures were adapted from published 
work evaluating the effects of chemical alteration of vitronectin on the cellular binding 
and processing of the protein by fibroblasts [129].  To follow binding and degradation of 
vitronectin, the protein was labeled with Iodine-125 using a method that employs 
lactoperoxidase and glucose oxidase [129].  Since the studies described here aim to 
evaluate the effects of ligand-induced multimerization of the plasma form of vitronectin, 
it was imperative that radiolabeling did not result in oligomerization.   
 As shown in Figure 3-1, labeling of vitronectin with iodine did not cause the 
formation of disulfide-linked oligomers that are seen when the protein is altered by 
treatment with urea.  SDS-PAGE analysis under non-reducing conditions show the 
formation of high-molecular weight complexes for the chemically-induced multimer of 
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Fig. 3-1. SDS-PAGE analysis of iodinated-vitronectin. 125-Iodine-labeled native 
vitronectin and chemically denatured vitronectin were analyzed by SDS-PAGE under 
reducing and non reducing conditions.  Gels were electrophoresed and dried followed 
by exposure onto film.  
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 vitronectin also labeled with radioisotope.  A very small amount of high-molecular 
species (~200 kDa) was generated upon 125I-labeling of plasma vitronectin, with the 
majority of protein present in the monomeric form.  These results indicated that our 
labeled protein would be appropriate for studies investigating the interaction of 
vitronectin with fibroblast upon PAI-1-induced multimerization.  
 Figure 3-2 demonstrates that complex formation with PAI-1 results in an enhanced 
level of vitronectin turnover by fibroblasts when cultures are incubated at 37°C for 5 
hours.  The PAI-1 effects on uptake and degradation of vitronectin by the fibroblasts are 
dose-dependent, saturating at a PAI-1:vitronectin molar ratio near 2:1.  These new 
findings establish that higher-order species of vitronectin, which can arise in a biological 
setting when bound to PAI-1, are degraded more effectively by cells than the monomeric, 
circulatory form of vitronectin.  This turnover is presumed to be a direct consequence of 
increased binding of the complexes to the cell layer. Several experimental strategies were 
pursued to test the mechanism of processing of the higher-order complexes by the 
fibroblasts. 
      
 PAI-1 Promotes Increased Binding of Vitronectin to Human Fibroblast 
Monolayers—The mechanism for increased cellular turnover of vitronectin induced by 
PAI-1 involves a series of events, with binding to the cell-matrix layer as the obligatory 
first step.  To determine if PAI-1/vitronectin complexes exhibit enhanced binding to cell 
surfaces and/or deposition of the protein onto the ECM of cultured fibroblasts, binding 
experiments were conducted at 4 °C.  Results in Figure 3-3 show increased association of 
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Fig. 3-2.  Vitronectin degradation by human fibroblasts is dependent on PAI-1 
binding. Human fibroblasts were grown to confluence and treated with ascorbate
for 3 days as described in Materials and Methods.  Confluent monolayers were 
cultured in DMEM media containing exogenous 125I-labeled vitronectin either in its 
native conformation or complexed with varying molar ratios of PAI-1.  Degradation 
was carried out over 5 hours at 37°C in DMEM, and the amount of vitronectin
degraded was determined by measuring the radioactivity present in TCA-soluble 
fractions of cultured media.  Results, initially calculated as the percent of vitronectin
degraded as described in Materials and Methods, are expressed as relative values 
normalized to the maximal value observed at a PAI-1:vitronectin ratio of 8:1 (11 % 
degradation).  Error bars represent standard errors.
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Fig. 3-3.  PAI-1 binding enhances the association of vitronectin with fibroblast 
monolayers. Human fibroblasts were grown to confluence and treated with 
ascorbate for 3 days as described in Materials and Methods.  Exogenous 125I-
labeled vitronectin alone, or labeled vitronectin combined with varying molar ratios 
of PAI-1, were added to the fibroblast monolayers.  Cell binding was conducted 
over 5 hours at 4°C in DMEM, and the amount of vitronectin bound was 
determined by measuring the radioactivity present on monolayers washed 3 times 
with PBS.  Results, initially calculated as the percent of vitronectin bound as 
described in Materials and Methods, are expressed as relative binding normalized 
to the maximal value observed at a PAI-1:vitronectin ratio of 4:1 (2 % bound).  
Error bars represent standard errors.
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 125I-vitronectin with fibroblast monolayers as the amounts of the serpin PAI-1 increase.  
Again, the effect is dose-dependent, with maximal binding at a stoichiometry of 
approximately 2:1 PAI-1/vitronectin.   
 To investigate the potential role of GAGs present on fibroblast monolayers, binding 
studies were carried out using sodium chlorate, a competitive inhibitor in the binding of 
sulfate to ATP sulfurylase, an enzyme involved in formation of the biological sulfate 
donor, 3’-phosphoadenosine 5’-phosphosulfate [149,150].  This leads to the synthesis of 
proteoglycans containing GAG chains that are depleted of sulfate groups [151-153].  
Results presented in Figure 3-4 illustrate that binding of the PAI-1/vitronectin complexes 
to cell monolayers is dependent on sulfated GAGs.  When PAI-1/vitronectin complexes 
were added to fibroblasts that had been pretreated for 2 days with chlorate, there was a 
50% decrease in the relative level of vitronectin bound to the fibroblast monolayers. 
 
 Binding of Vitronectin/PAI-1 Complexes to Fibroblast Monolayers is Dependent on 
the Presence of Active PAI-1—To test the potential role of PAI-1 in the binding of 
vitronectin/PAI-1 complexes, experiments like those described in Chapter 2 using tPA-
mediated release of PAI-1 were utilized.  Here, complexes of vitronectin and PAI-1 were 
allowed to form for 5 minutes or 1 hour, and then complexes were treated with tPA to 
dissociate bound PAI-1 and prevent any further binding of PAI-1 to vitronectin (i.e. tPA 
was presented in saturating amounts relative to PAI-1).  Results shown in Figure 3-5 
demonstrate that release of PAI-1 from oligomeric complexes results in a significant 
decrease in the amount of vitronectin associated with fibroblastic monolayers.  These 
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Fig. 3-4.  Effect of chlorate treatment on vitronectin binding to fibroblast 
monolayers in the presence and absence of added PAI-1. Confluent ascorbate-
treated fibroblast monolayers were incubated for 2 days with 50 mM sodium 
chlorate in DMEM supplemented with 10% FBS.  Both chlorate-treated and non-
treated cells were cultured in media lacking FBS and containing 125I-vitronectin 
alone or vitronectin mixed with PAI-1 (4:1 molar ratio of PAI-1:vitronectin).  Cell 
binding was carried out as described in Materials and Methods.  Results are 
presented as the percentage of total vitronectin associated with monolayers, 
compared to the amount present when PAI-1/vitronectin mixtures were added to 
non-chlorate treated cells.  Error bars represent standard errors.
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Fig. 3-5.  Effect of tPA-mediated release of active PAI-1 on vitronectin binding 
to fibroblast monolayers. Confluent ascorbate-treated fibroblast monolayers were 
cultured in media lacking FBS and containing 125I-vitronectin mixed with PAI-1 
(2:1 molar ratio of PAI-1:vitronectin).  Following mixing, tPA was added in 
equimolar amounts with PAI-1 at time of mixing or 1 hour after.  Cell binding was 
carried out as described in Materials and Methods.  Results are presented as the 
percentage of total vitronectin associated with monolayers, compared to the amount 
present when PAI-1/vitronectin mixtures were added in the absence of tPA.  Error 
bars represent standard errors.
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 results were identical regardless of when tPA was added following mixing of PAI-1 and 
vitronectin, indicating the requirement for PAI-1 in complex formation and stability.  
Findings presented in Chapter 4 of this dissertation demonstrate the involvement of PAI-
1 in directly stabilizing higher-order complexes formed with vitronectin.  Importantly, 
these results do not exclude the possibility that PAI-1 mediates the interaction of the 
vitronectin/PAI-1 complex directly by self-engagement with cell/matrix components.  
Indeed, previous evidence has shown that PAI-1 can interact with certain ECM 
molecules, including glycosaminoglycans [154,155] 
 
 Immunofluorescent Localization of Vitronectin and PAI-1 Demonstrates the 
Effects of Complex Formation on Fibroblast Association and Degradation—To 
complement these data indicating that PAI-1 complexing of vitronectin promotes its 
increased binding to fibroblasts, and subsequent endocytosis and degradation, 
immunofluorescent microscopy was used to evaluate the cellular binding and 
internalization of vitronectin and PAI-1.  Fibroblasts were grown to confluence or near-
confluence and were incubated with medium containing biotinylated-vitronectin alone or 
in complex with PAI-1.  The mixtures were incubated at 37 °C for 30 minutes, a time 
sufficient for binding and endocytosis by cells.  Cells were fixed, permeablized and 
stained for vitronectin using fluorescently-tagged streptavidin.  Images presented in 
Figure 3-6 demonstrate noteworthy differences, with no detectable binding of monomeric 
vitronectin (panel A), compared to clear association of PAI-1/vitronectin complexes 
(panel B) with the cell layers.  The addition of PAI-1 to vitronectin results in a stronger 
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Fig. 3-6.  Effects of PAI-1-induced formation of higher-order complexes on the 
cellular localization of vitronectin on human fibroblasts. Human fibroblasts 
were cultured on glass microscope slides in DMEM treated with chloroquine.  Cells 
were incubated with biotinylated vitronectin either in the native conformation 
(panel A) or as multimers induced by PAI-1 (panels B-D).  Cell monolayers were 
incubated at 37°C for 30 minutes and then washed, fixed with paraformaldehyde, 
and permeabilized with Triton X-100.  Vitronectin was detected using FITC-
conjugated streptavidin.  Fibroblasts shown in panels A and B were present as 
confluent layers whereas those shown in panels C and D were non-confluent.  
Panel D shows a phase-contrast image with overlaying staining for PAI-1 induced 
multimers of vitronectin.  Magnification was 40x (panels A-C) or 100x (panel D). 
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 staining intensity for vitronectin associated with the ECM and/or the A1-F fibroblasts.  
Similar findings were observed for non-confluent cells, and also present is a punctate 
staining pattern for vitronectin that clearly co-localizes to fibroblasts (panel C).  This 
punctate pattern is shown more clearly in the 100X magnified image presenting a phase-
contrast image combined with immunostaining for vitronectin (panel D).  This magnified 
image shows the cytosolic localization of these foci, suggesting that vitronectin is taken 
up into intracellular vesicles.   All images in Figure 3-6 were recorded on cells treated 
with chloroquine, experimental conditions that gave larger foci compared to cells 
cultured in the absence of chloroquine.  Chloroquine inhibits the degradation of proteins 
by raising the pH within the lyososome from its optimum.  The accumulation of larger 
foci under these conditions indicates that the punctate staining pattern observed reflects 
the processing of vitronectin within lysosomal vesicles.  These results on the PAI-
1/vitronectin complexes have been followed up with confocal microscopy that confirms 
these foci to be cytoplasmic vesicles rather than cell surface or matrix-associated 
structures.   
 As mentioned above, the immunostaining pattern that demonstrates an increase in 
vitronectin association with the cultured fibroblasts has features correlated both with 
increased binding to and processing by the cells (through lysosomes).  To directly test 
whether there is an increase in vitronectin deposition in the ECM, immunolocalization 
experiments were implemented with matrices produced by the fibroblasts in culture.  
Cells were grown to near confluence and exposed to monomeric vitronectin or PAI-
1/vitronectin mixtures as described above.  After the 30-minute incubation with the 
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 fibroblast cultures, the cells were removed from the underlying ECM by treatment with 
ammonium hydroxide so that images of the isolated acellular matrix could be recorded.  
As shown in Figure 3-7, there is a marked increase in the amount of vitronectin staining 
associated with ECM fibrils when PAI-1 is present to promote formation of the higher-
order vitronectin complexes.  Figure 3-7 (panel B) shows the result at 40X magnification, 
where there is clearly more immunostaining in the presence of PAI-1 compared to 
experiments with monomeric vitronectin alone (panel A).  Two different images recorded 
at 100X magnification show staining patterns observed with the PAI-1/vitronectin, 
representing the somewhat amorphous staining patterns observed in some fields (panel 
C) and also the clear fibrillar patterns observed in other regions of the ECM (panel D). 
 To test the postulate that vitronectin and PAI-1 in the higher-order complexes are 
internalized together for processing within the same intracellular vesicles, dual staining 
experiments were carried out using both biotinylated vitronectin and monoclonal 
antibodies directed against PAI-1.  Images in Figure 3-8 (panels A and B) demonstrate a 
similar staining pattern for vitronectin and PAI-1 when the proteins were added to 
fibroblast cultured on microscope slides and treated with chloroquine.  A merged image 
(panel C), shows a co-localization pattern for vitronectin and PAI-1 when the individual 
stains are overlaid.  Confocal analysis also demonstrated the intracellular co-localization 
of most of the positively stained vesicles (data not shown).  These findings support a 
mechanism by which PAI-1 associates with vitronectin into higher-order complexes that 
exhibit enhanced association and degradation by fibroblasts.  It appears from these 
studies that the two proteins in the complex are internalized in the same fashion. 
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Fig. 3-7.  Immunofluorescent localization of vitronectin demonstrates 
enhanced binding of higher-order PAI-1/vitronectin multimers to ECM. A1-
F fibroblasts were grown to confluence on glass slides and then removed using 
0.02 M ammonium hydroxide.  Isolated ECM was washed with PBS and then 
incubated with biotinylated vitronectin in the native form or in the PAI-1 induced 
multimeric form in DMEM for 1 hour.  Vitronectin bound to the matrix was 
detected using FITC-conjugated streptavidin.  Panel A represents ECM isolated 
from cells cultured with native vitronectin and Panels B-D represent ECM 
isolated from those cultured with vitronectin in complex with PAI-1.  
Magnification was 40X (panels A and B) or 100x (panels C and D).
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Fig. 3-8.  Fluorescent microscopy demonstrates the co-localization of vitronectin
and PAI-1 on human fibroblasts. Human fibroblasts were cultured on glass 
microscope slides in DMEM treated with chloroquine as described in Materials and 
Methods.  Cells were subsequently incubated with DMEM containing biotinylated
vitronectin in complex with PAI-1.  Cell monolayers were incubated with the 
complexes at 37 °C for 30 minutes and then washed, fixed with paraformaldehyde, 
and permeabilized with Triton X-100.  Vitronectin was detected using streptavidin
(panel A) and PAI-1 was detected using a monoclonal antibody raised against human 
PAI-1 (panel B).  The image in panel C represents an overlay of vitronectin and PAI-1 
immuno-staining.  All images were collected at 40x magnification.
10 µm
A                    B                   C
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 Turnover of PAI-1/Vitronectin Complexes by A1-F Fibroblasts is Partially 
Integrin-Dependent—To investigate the mechanism of uptake of the PAI-1/vitronectin 
complexes by the cells, the potential role of integrins was tested.  It was previously 
shown that the chemically altered multimeric vitronectin is internalized by human 
fibroblasts in an integrin-dependent fashion, specifically via αvβ5 [65,129,141].  In this 
study, an antibody specific for the αvβ5 integrin and an RGDS peptide were used to carry 
out competition studies for cell turnover of vitronectin.  As shown in Figure 3-9 (panel 
A), the antibody and the RGDS peptide only partially inhibited the degradation of the 
higher-order vitronectin complexes with PAI-1 (approximately 15% and 30%, 
respectively).  These results indicate that other, possibly non-integrin mediated, processes 
are involved in the uptake and degradation of vitronectin.  At least one possiblity would 
be a direct involvement of PAI-1 in uptake of vitronectin complexes, potentially through 
interactions with PAI-1-receptors like uPAR and low-density LRP receptor. 
 Results in Figure 3-9 (panel A) also demonstrate that degradation of PAI-1 induced 
multimers of vitronectin is inhibited by chloroquine.  Chloroquine diminished the 
degradation of 125I-labeled vitronectin complexes with PAI-1 by greater than 50%.  These 
findings are in agreement with the augmented punctate staining pattern observed by 
microscopy (above) and also with studies on chemically-induced multimeric forms of 
vitronectin indicating that the uptake of the protein by integrins is coupled to lysosomal 
degradation [65,129,141].   
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Fig. 3-9.  Cell turnover and binding experiments demonstrate the role of 
integrins and native PAI-1 in the turnover of vitronectin by fibroblasts. Panel 
A: Degradation experiments using exogenous 125I-labeled vitronectin in complex 
with PAI-1 demonstrate the partial inhibition of vitronectin turnover by chloroquine, 
antibody specific for avb5 (50 µg/ml), and RGDS peptide (0.5 mM).  Panel B: 
Binding experiments were implemented using vitronectin alone, vitronectin plus 
wild-type PAI-1, or vitronectin plus the 14-1B stable mutant form of PAI-1.  Results 
in both panels are presented as the percent of degradation or binding of vitronectin
relative to the levels observed for vitronectin + PAI-1 (1:4 vitronectin:PAI-1 molar 
ratio) in the absence of inhibitors.  Error bars represent standard errors.
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  Enhancement of Vitronectin Binding to Fibroblast Monolayers is Dependent on 
the Native Structure of PAI-1—A unique property of PAI-1 among other serpins is its 
propensity to convert to a latent, inactive form that can neither inhibit plasminogen 
activators, nor bind to vitronectin.  Stable forms of PAI-1 that do not readily convert to 
the latent form have been generated from site-directed mutagenesis studies incorporating 
amino acid replacements in the central β-sheet core of the protein [156-160].  Because of 
potential experimental complications that may arise due to the inherent slow rate of 
conversion to latency by native PAI-1, many researchers have opted in their studies to 
use the stable variant of PAI-1 that has been best characterized [157,158]  This PAI-1 
variant, denoted 14-1B, contains 4 mutations (Asn150His; Lys154Thr; Gln319Leu; 
Met354Ile) and is the form of PAI-1 that has been crystallized [160].  These mutations 
result in a delay in the transition of PAI-1 to latency by approximately 70-fold, with no 
reported change in inhibition of tPA or uPA.  Although many current structural and 
functional studies rely on the use of the stable 14-1B PAI-1, it appears that there are some 
distinctions between native PAI-1 and the stable conformer.  For example, uPA reacts 
differently with native PAI-1 and the 14-1B variant in the presence of the non-ionic 
detergent Triton X-100, with a reduction in the inhibitory activity against both forms 
[161].  Because of the possibility that there may be important structural and/or functional 
differences, the stable 14-1B variant was compared to native PAI-1 in the fibroblast 
binding assay. 
 As shown in Figure 3-9 (panel B), the enhanced binding by fibroblasts of the PAI-
1/vitronectin complexes is observed with native PAI-1, but not with the 14-1B variant.  
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 When 125I-labeled vitronectin was complexed with the 14-1B stable variant of PAI-1, no 
differences were seen in vitronectin binding to the cellular monolayers when compared to 
monomeric vitronectin.  Therefore, the function of PAI-1 in promoting higher-order 
complexes that assume an adhesive role in binding to cells and matrices clearly relies on 
the native structure of PAI-1.  Interestingly, results in Chapter 4 evaluating the ability of 
PAI-1 to promote higher-order oligomerization of vitronectin demonstrate that 14-1B 
PAI-1 does not induce oligomerization to the extent that the wild-type form does.   
  
Discussion   
  The study presented in this chapter strongly supports the findings discussed in 
Chapter 2, where vitronectin/PAI-1 complexes displayed enhanced association with both 
cell surface receptors and isolated ECM when compared to monomeric vitronectin alone.  
By utilizing a living system, we gain more physiological support regarding our model 
that vitronectin/PAI-1 complexes display adhesive properties that develop through the 
process of ligand-induced multimerization of vitronectin.  Our system for studying our 
model is based on using human fibroblast, and was optimized for studying the adhesive 
properties of vitronectin by our collaboraters (Dr. Paula McKeown-Longo laboratory) at 
Albany Medical School in New York.  The results presented here provide new evidence 
that PAI-1/vitronectin complexes display enhanced interactions with human fibroblast 
monolayers, an event that would be significant during homeostatic responses such as 
wound healing and tissue remodeling.  In this study, uptake and degradation of 
vitronectin was monitored to follow the engagement of the protein with fibroblast cell 
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 surfaces.  It is important to note that the aim of this study was to merely use this system 
to indirectly monitor the active engagement of vitronectin with fibroblast cell surfaces, 
and not to specifically address questions regarding the physiological importance and 
consequences of vitronectin and/or PAI-1 clearance and degradation.  Although this latter 
aim is important and several hypotheses might be drawn based on the results presented 
here, our intention was focused mainly on evidence of cell surface binding.  In fact, it 
would be in the interest of this laboratory to evaluate other downstream consequences of 
vitronectin binding to cell surface receptors including signaling, cytoskeletal 
rearrangements, and cellular motility. 
   When found in higher-order complexes with PAI-1, vitronectin interacts with cell 
monolayers and is subsequently endocytosed and degraded to a greater degree than native 
vitronectin.  Maximal effects are observed at a stoichiometry near 1:2 (vitronectin:PAI-
1), in keeping with the biophysical analyses in Chapter 2 of complexes formed in the 
isolated systems that show the same binding stoichiometry [128].  Interestingly, PAI-1 
seems to be required for enhanced binding of complexes to monolayers, as demonstrated 
at early times by the addition of tPA.  Immunofluorescent microscopy demonstrates the 
enhanced uptake of vitronectin when bound to PAI-1, documents increased deposition of 
the protein in the ECM, and shows that both proteins are present within similar 
intracellular vesicles.  Binding of PAI-1/vitronectin complexes is dependent on properly 
sulfated GAGs on the fibroblast monolayer.  Recent work with an HT1080 cell line has 
demonstrated that binding of vitronectin to the cell layers is mediated via a specific 
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 interaction of the basic heparin-binding domain of vitronectin interacting with the 
transmembrane heparan sulfate proteoglycan, syndecan  [162] 
 Interestingly, the effects also are limited to complexes formed with the native form of 
PAI-1.  Specific differences between native PAI-1 and the 14-1B stable variant must 
await further detailed structural analysis; it is not possible at this time to attribute 
properties of the complexes either to structural nuances or to differences in the kinetics of 
formation/breakdown of the complexes that are tied to the active to latent conversion of 
PAI-1.  However, analytical ultracentrifugation results presented in the following chapter 
demonstrate clear differences in the effectiveness of wild type and the stable form of 
PAI-1 in promoting formation of higher-order complexes.  The hypothesis that PAI-1 
confers an adhesive role on vitronectin via formation of higher-order species is supported 
by these data and also by the differences observed in our cell-matrix binding experiments 
for the two forms of PAI-1.   
 The mechanism by which PAI-1/vitronectin complexes that associate with the 
cell/matrix layer in fibroblast culture are subsequently taken up and degraded depends to 
an extent on the cell surface integrin, αvβ5.  The evidence for involvement of this receptor 
comes from inhibition studies presented here using antibodies specific for αvβ5, as well 
as RGD peptides.  McKeown-Longo et al. [141] have demonstrated a role of this integrin 
in the removal of chemically-altered vitronectin from the ECM of fibroblast monolayers 
and subsequent lysosomal degradation.  We demonstrate only a partial inhibition, 
indicating the potential role of other receptors and/or potential non-RGD-dependent 
integrin binding sites on vitronectin [46]  Another plausible mechanism that needs further 
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 consideration is the direct role of PAI-1 in associating higher-order vitronectin complexes 
with cell surfaces that leads to uptake and degradation.  The presence of PAI-1 in the 
higher-order complexes should influence the internalization of vitronectin/PAI-1 
complexes, via interactions with other known cell-surface receptors for PAI-1 such as 
uPAR and/or the low-density lipoprotein receptor-related protein. 
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CHAPTER 4 
 
A MECHANISM FOR ASSEMBLY OF COMPLEXES OF 
VITRONECTIN AND PAI-1 FROM SEDIMENTATION VELOCITY 
ANALYSIS* 
 
 
 
*This chapter is a revised version of a manuscript under the same title published in the 
Journal of Biological Chemistry in 2005 by Kenneth H. Minor, Christine R. Schar, Grant 
E. Blouse, Joseph D. Shore, Daniel A. Lawrence, and Cynthia B. Peterson [163]. 
 
Minor K. H., Schar C. R., Blouse G. E., Shore J. D., Lawrence D. A., and Peterson C. B.  
A mechanism for assembly of complexes of vitronectin and plasminogen activator 
inhibitor-1 from sedimentation velocity analysis.  Journal of Biological Chemistry  280 
(31):  28711-28720. 
 
My contributions to this paper include: (1) aiding in the development and design of 
experimental goals and procedures, (2) performing all experiments and collections of 
data, (3) analyzing collected data, (4) helping initiate the development of the multisignal 
analysis of sedimentation velocity data  using the program SEDPHAT in collaboration 
with Dr. Peter Shuck, (5) designing how the results were illustrated, and (6) writing and 
publication of the work in collaboration with my mentor Dr. Cynthia Peterson. 
 
 
Introduction 
Results given in Chapters 2 and 3 [128,140] support a model in which binding to PAI-1 
leads to the functional conversion, or “activation” [Bloemendal, 2004 #286;Minor, 2005 
#347] of vitronectin from a circulating form into a tissue-associated, pro-adhesive form.  
PAI-1-induced activation of vitronectin involves the formation of multivalent PAI-
1/vitronectin complexes that assemble into the ECM and readily associate with cell-
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 surface receptors.    What is the mechanism of assembly of higher-order PAI-
1/vitronectin complexes that are targeted to the ECM?  What types of intermediates 
and higher-order species are formed? What are the concentration- and time-
dependencies of the assembly process?   
 Sedimentation velocity experiments were used to observe the types of vitronectin/PAI-
1 that build off the 1:2 and 2:4 (vitronectin:PAI-1) complexes that are reported to form 
[127].  These studies were also used to test the effects of time, ionic strength, and protein 
concentration on the assembly of higher-order complexes.  In short, the results described 
in this chapter provide valuable information regarding the step-wise formation of 
vitronectin/PAI-1 complexes, and give further insight into how complex formation 
between these two proteins may support adhesive processes during wound healing and 
tumor metastasis.   
 Vitronectin is localized predominantly in circulation with plasma concentrations in the 
micromolar  range.  This concentration is constantly maintained with vitronectin present 
in a monomeric form with a mass of approximately 62 kilodaltons.  However, altered 
multimeric forms of the protein are also found in certain tissues, especially those under 
insult by vascular injury and/or tumor metastasis.  Since most cells do not synthesize 
vitronectin, the mechanism by which vitronectin becomes deposited into the ECM most 
surely involves the active movement of the protein from circulation into the tissue matrix.  
Although the ramifications of this circulation-matrix exchange of vitronectin are well-
studied, especially those related to the cellular adhesive properties, the actual mechanism 
that results in this exchange is unknown. 
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  Mechanisms that recruit soluble matrix proteins to the pericellular environment are 
well documented with several ECM components [2].  Denaturation and oligomerization 
are mechanisms through which components like fibronectin, collagens, and 
fibrinogen/fibrin become associated with tissue matrices.  These two mechanisms can 
result from enzymatic modifications as well as from interactions with biological ligands.  
Regarding vitronectin, several studies have shown that certain ligands, including 
plasminogen-activator type-1 (PAI-1), thrombin-antithrombin complex (T-AT), and 
complement C5-6b, can form oligomeric structures with altered structural and functional 
properties [119,121,164].   Is formation of oligomeric vitronectin-ligand complexes the 
route through which vitronectin shifts from circulation to tissue?  It is intriguing that each 
of the vitronectin ligands mentioned here are all active in matrix remodeling processes, 
including those linked to injury and metastasis of tissues.  
A working hypothesis for this work poses that vitronectin becomes readily deposited 
into tissues following damage from injury or cancer through a mechanism involving 
ligand-induced formation of multivalent, adhesive complexes.  Formation of these 
complexes results in significant alterations in the functional properties of vitronectin that 
in turn can have profound effects on both local and invading cells.  Recent studies like 
those presented in Chapters 2 and 3 demonstrate that the interaction of vitronectin with 
the main inhibitor of fibrinolysis, PAI-1, results in the assembly of large complexes that 
display enhanced association with cell-surface integrins and ECM components, including 
glycosaminoglycans [128].  Relevant to these studies, localization experiments 
demonstrate that PAI-1 levels increase following tissue injury and during tumor invasion, 
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 and that this is correlated with vitronectin/PAI-1 deposition into the surrounding matrix.  
Intriguingly, PAI-1 expression is linked to several types of cancer, including cancer of 
the lung, breast, colon, and skin [165-167], where it is speculated to play a role in tumor 
angiogenesis and invasion.  Importantly, high levels of PAI-1 correlate with later-stage 
tumors and poorer clinical prognosis. 
 To begin obtaining information regarding the ability of PAI-1 to act as a regulator in 
the compartmentalization of vitronectin between circulation and the ECM, we propose to 
fully characterize the biochemical mechanism involved in the assembly of higher-order 
vitronectin/PAI-1 complexes that become adhesive in nature.  This characterization will 
involve addressing the following questions:   
 
Materials and Methods 
 Purification and Fluorescent Labeling of Vitronectin—Native, monomeric vitronectin 
was purified from human blood plasma using a modified protocol of the method 
developed by Dahlback and Podack [133,134].   For multi-wavelength studies, 
vitronectin was labeled with FITC using a FluoReporter® protein labeling kit (Molecular 
Probes, Inc., Eugene, OR) that labels primary amines.  The molar ratio of dye to 
vitronectin in the labeling reaction typically resulted in conjugation of ~2 fluorescein 
molecules per vitronectin monomer; labeling ratios varied from 1.5 to 1.8 mol fluorescein 
per mol vitronectin.  The labeled vitronectin monomer was fully functional, with no 
adverse effects of labeling on PAI-1 binding.  
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  Mutagenesis, Expression and Purification of Recombinant PAI-1—The stable I4-1B 
mutant PAI-1 [158] and latent PAI-1 were obtained from Molecular Innovations, Inc.  
The W175F variant [168] and PAI-1R (PAI-1 containing two amino acid replacements, 
T333R and A335R [169]) were produced as described (and [169], respectively).  The 
recombinant human PAI-1 gene was cloned into the pET-24d vector (Novagen) as 
described previously [170].  The M347C (P1'-Cys) form of PAI-1 was engineered by 
site-directed mutagenesis using the Muta-Gene Phagemid In Vitro Mutagenesis kit (Bio-
Rad) using the mutagenic oligo 5’1125-
dGATCTCCTCGGGGGCACAGCGGGCTGAGACTAT-3’1093.  All mutations were 
confirmed by DNA sequencing of the full length PAI-1 gene.   
 Mutant and wild-type PAI-1 constructs were expressed in the E. coli strain 
BL21(DE3)pLysS and purified as described [170].  Labeling of the P1'-Cys PAI-1 variant 
with 5-iodoacetamidofluorescein (Molecular Probes) was carried out as described 
previously with a labeling efficiency of 1-1.2 moles of 5-iodoacetamidofluorescein per 
mole of PAI-1 variant.  Latent PAI-1 that typically accumulated during the labeling 
reaction was removed by affinity chromatography on immobilized β-anhydrotrypsin as 
described [168].  All final unlabeled and P1'-fluorescein labeled preparations were shown 
to be >98% active by detecting a stable, inactive acyl-enzyme complex with tPA using 
SDS-PAGE analysis [168,170].  PAI-1 protein concentrations were determined from 
absorption at 280 nm, using a Mr of 43,000 and extinction coefficients of 0.93 mL mg-1 
cm-1 for wild-type PAI-1 or 0.83 mL mg-1 cm-1 for W175F PAI-1 [168].  Concentrations 
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 of labeled P1'-fluorescein PAI-1 were determined by the Bradford dye-binding assay 
(Bio-Rad) using wild-type PAI-1 as the standard [171]. 
 
 Sedimentation Velocity Experiments.—A Beckman Optima XL-I analytical 
ultracentrifuge equipped with both absorbance and interference optical detection systems 
were used to follow the formation of higher-order complexes between vitronectin and 
PAI-1.  Epon double-sector centerpieces were filled with 400 µl of samples containing 
either vitronectin or PAI-1 alone, or mixtures of the two at varying molar ratios.  All 
samples were first dialyzed extensively against PBS.  For all experiments, the dialysate 
was loaded into the reference sector.  Samples were centrifuged at a rotor speed of 50,000 
rpm, and data were collected in fringes using interference optics and/or by absorbance at 
494 nm, the extinction maximum for fluorescein.   
 
 Hydrodynamic Modeling of the Sedimentation Velocity Data—Sedimentation velocity 
analyses were performed with the program SEDFIT (available online from 
http://www.AnalyticalUltracentrifugation.com) as described in detail in [172] that carry out 
size distribution analyses based on Lamm equation modeling [173-175].  Briefly, the 
analysis of velocity profiles was performed by direct boundary modeling by distributions of 
Lamm equation solutions c(s) with  
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 a(r, t) ≅ c(s)χ1(s,F,r,t)ds + b(r) + β(t)
smin
smax∫  
 
  (Eq. 1) 
where a(r,t) denotes the measured absorbance or interference profiles at position r at time t, 
b(r) and β(t) the characteristic systematic offsets [175], and χ1(s,F,r, t) solutions of the Lamm 
equation  
     
                  
                      (Eq. 2) 
(with ω denoting the rotor angular velocity, D the diffusion coefficient and s the sedimentation 
coefficient) at unit loading concentration.  D and s are related via the frictional ratio F = 
(f/f0) and the hydrodynamic scale relationship  
 
 
 
(with η and ρ the solvent viscosity and density, respectively, and v the partial-specific 
volume of the macromolecules, which were calculated using the software SEDNTERP 
[174,176].  The non-linear regression with Eq. 1 was combined with the determination of 
the best-fit weight-average frictional ratio, the best-fit meniscus position, and the algebraic 
calculation of systematic time-invariant and radial-invariant noise components, and maximum 
∂χ
∂t =
1
r
∂
∂r rD
∂χ
∂r − sω
2r2χ⎡ ⎣ ⎢ 
⎤
⎦⎥
D(s) = 2
18π kTs
−1/ 2(ηF)−3 / 2((1−ν ρ /ν )1/ 2
(Eq.3) 
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aλ(r,t) ≅ εkλ
k=1
K∑ ck (s)χ1
smin
smax∫ (s,Fk,wr,t)ds λ =1K Λ, K ≤ Λ  
entropy regularization at a confidence level of 0.70.  Because these systematic signals are 
arbitrary offsets introduced from the detection system, calculated systematic offsets can be 
subtracted from the raw data without introduction of bias if the degrees of freedom in the 
analysis are not reduced.  Therefore, the final calculated best-fit offsets are subtracted from 
the raw data for presentation purposes.  In all calculations, both meniscus and frictional ratio 
parameters were optimized by carrying out non-linear regression to obtain best fits.  s-values 
were converted to standard conditions in water at 20°C with the program SEDNTERP 
[174,176]. 
 
 Multi-Signal Analysis of Sedimentation Data for Fluorescently-Labeled PAI-
1/Vitronectin Mixtures—Sedimentation velocity data acquired simultaneously at different 
signals (refractive index and absorbance) were globally modeled with a superposition of 
component sedimentation coefficients ck(s) according to  
 
 
                                        (Eq. 4) 
where εkλ denotes the extinction coefficient (or generalized signal increment) of component k 
at signal λ. This multi-signal generalization of Eq. 1 for heterogeneous protein interactions is 
described in detail elsewhere [177], and was implemented in the software SEDPHAT 
(http://www.AnalyticalUltracentrifugation.com).  Briefly, the extinction coefficients were 
pre-determined in separate experiments with each protein component alone.  As a result, the 
global modeling of data acquired at different wavelengths (or signals) permits a spectral 
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 distinction of the different sedimenting protein components, and allows for separate 
deconvolution of the sedimentation coefficient distributions ck(s) of species containing 
protein component k.  Although this may lead also to slightly enhanced deconvolution of the  
hydrodynamic separation, it has very similar properties as the c(s) with regard to the 
influence of reaction kinetics on the obtained sedimentation coefficient distributions [173].  
Reactions that are fast on the time-scale of sedimentation can be diagnosed by concentration-
dependent peak positions in ck(s) which reflect the characteristic s-values of the reacting 
system, but with different ck(s) still reflecting the correct stoichiometry [177].  Like c(s) 
[173,174], reactions that are slow on the time-scale of sedimentation, as those studied in 
the present communication, result in peak positions of ck(s) that correspond to different 
sedimenting species.   
 
Results 
 Characterization of PAI-1 and Vitronectin—The design of this study is to use 
hydrodynamic methods to critically evaluate the formation of PAI-1/vitronectin 
complexes.  The SV method, which provides first-principle hydrodynamic information 
concerning the size, shape and stoichiometries of macromolecules in heterogeneous 
populations of interacting species, was adopted to characterize all complexes that form 
upon PAI-1 binding to vitronectin.   
 As a first step in the analysis, experiments were conducted to characterize the 
hydrodynamic properties of the individual proteins.  Figure 4-1 shows the sedimentation 
profiles for PAI-1 and vitronectin (Panels A and B, respectively), and the sedimentation 
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Fig. 4-1. Sedimentation velocity analysis of PAI-1 and vitronectin using SEDFIT.
PAI-1 (3.5 µM) and vitronectin (3.5 µM) were analyzed individually by 
ultracentrifugation at 50,000 rpm at 22 °C in a Beckman-Coulter XL-I analytical 
ultracentrifuge.  Sedimentation of proteins was monitored by interference detection.  
SV data were analyzed using a continuous c(s) distribution model implemented in 
the program SEDFIT.  Partial specific volumes calculated on the basis of amino acid 
and carbohydrate content for recombinant PAI-1 and human vitronectin were 0.74 
and 0.705 ml·g-1 (listed in Table 4-I.  The frictional ratio for each sample was a fitted 
parameter in the SEDFIT analysis.  Representative SV data, with global fits to each 
data set, are shown for PAI-1 and vitronectin in panels A and B, respectively.  
Resulting residuals for each analysis are given below each SV profile.  Scans were 
collected at approximate 11-min intervals.  All data were included in the calculation 
of c(s) distributions.  c(s) distribution profiles for the two proteins are shown in panel 
C (black line, PAI-1; blue line, vitronectin).
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 coefficient distributions c(s) for both PAI-1 and vitronectin obtained from these analyses 
(Panel C).  For both samples, a major species is apparent, with peak s-values centered at 
3.4 and 4.2 S for PAI-1 and vitronectin, respectively (Table 4-I).  This observation was made 
essentially independent of protein concentration.  The small peak at a higher s-value of 
6.2 S corresponds to a small amount of vitronectin dimer that appears to a variable extent 
in purified vitronectin samples [178].  The quality of fit was high, with R.M.S. deviations 
in both cases on the order of instrument noise.  The observed s-values are consistent with 
the monomeric state of the proteins, as summarized in Table 4-I that lists theoretical s-
values for spherical proteins of this size for comparison.  The best-fit frictional ratios 
(f/f0) were 1.2 for PAI-1 and 1.5 for vitronectin (Table 4-I).  This indicates a small degree 
of shape asymmetry for PAI-1, which is compatible with the dimensions of the protein 
known from crystallography [160].  For vitronectin, the series of SV experiments gave 
consistently a frictional ratio of 1.5-1.7, indicating that the protein is significantly asymmetric.  
This is supported by recent data using small-angle x-ray scattering on the native vitronectin 
monomer that indicate that the shape of the molecule deviates significantly from that of a 
sphere, yielding a bi-lobed shape with a maximal linear dimension of 110Å and average 
hydrodynamic radius of ~30Å [179]. 
 Mixtures of PAI-1 and Vitronectin Form Reversible Higher-Order Complexes—
With the goal of examining the mechanism of assembly of PAI-1/vitronectin complexes, SV 
experiments were conducted on mixtures of the two proteins under varying conditions.  As 
described in Chapter 2 [128], the complexes formed can be observed in size-exclusion 
chromatography and therefore dissociate slowly relative to the time-scale of the SV data 
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Table 4-I:  Sedimentation coefficients for PAI-1, vitronectin, and PAI-1/vitronectin complexes.
Species
Molecular 
Weight     
(Daltons)a
Partial        
Specific       
Volume       
(ml·g-1)b
Maximum      
Sedimentation  
Coefficient      
(ssphere )
c
Observed      
Sedimentation  
Coefficient     
(sobs )
d
Standard       
Sedimentation  
Coefficient      
(s20, w )
e
Frictional 
Ratio     
(f/f 0 )
f
Vitronectin                                    
(VN)
62,000 0.705 6.4 S 4.1 - 4.7 S 4.2 ± 0.2 S 1.5
PAI-1 43,000 0.740 4.3 S 3.2 - 3.7 S 3.4 ± 0.2 S 1.2
1 PAI-1: 1 VN 105,000 0.730 8.1 S 5.0 - 5.6 S 5.5 ± 0.2 S 1.5
2 PAI-1: 1 VN 148,000 0.730 10.2 S 6.0 - 6.7 S 6.5 ± 0.2 S 1.6
4 PAI-1: 2 VN 296,000 0.730 16.3 S 8.0 - 10.0 S 8.5 ± 0.5 S 1.8
aThe molecular weights of PAI-1 and vitronectin were calculated from both amino acid sequences and inclusion of 
carbohydrate content.
bPartial specific volumes for PAI-1 and vitronectin were calculated using SEDNTERP, whereas that for complexes was
fixed at 0.73.
cMaximum sedimentation coefficients for a spherical, non-hydrated molecule calculated using SEDFIT.
dRange in sedimentation coefficients observed under experimental conditions.
eSedimentation coefficients converted to standard conditions of 20 °C in water ± standard deviations; conversions 
were made using the SEDNTERP and SEDPHAT programs.
fFrictional ratios were determined using SEDFIT.
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 acquisition.  In other words, the dissociation constants of the complexes reflect rapid 
association and slow dissociation rates.  As a consequence, the peaks observed in c(s) analysis 
reflect the sedimentation rates of the different species formed stably during the time-frame of 
individual SV experiments [173,174,180].  Representative SV data on the PAI-1/vitronectin 
mixture are shown in Figure 4-2.  From the SV data acquired on an equimolar 8 µM mixture 
of vitronectin and PAI-1, three major peaks at s-values of 6.5, 8.6, and 10.9 S, respectively, 
were resolved in addition to several higher-order complexes ranging from ~12-25 S (Figure 
4-3, panel A).  Consistent with previous studies [119,127,128], the hydrodynamic profiles 
show that PAI-1 binds to vitronectin and results in the formation of a variety of complexes, 
including multiple higher-order oligomers. 
 To test the reversibility in assembly of these higher-order complexes, the equimolar 8 µM 
PAI1/vitronectin mixture was diluted to varying concentrations that were analyzed by SV 
(Figure 4-3, panels B and C). The results demonstrate that dilution over a concentration 
range from 8 µM to 1.6 µM significantly alters the c(s) distribution profiles of the PAI-
1/vitronectin mixtures.  As summarized in Table 4-I, the 1-5 S, 5.1- 7.4 S and 7.5-25 S 
intervals of sedimentation coefficients are hydrodynamically consistent with free 
vitronectin and/or PAI-1, intermediate 1:1 and 2:1 PAI-1/vitronectin complexes, and higher-
order complexes, respectively.  To quantify changes observed in Figure 4-3 (panels A-C) 
peaks within these three different ranges of s-values were integrated to obtain total 
amounts of the corresponding species (Table 4-II). 
 Only the distribution of PAI-1/vitronectin complexes, characterized by sedimentation 
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Fig. 4-2. Sedimentation velocity analysis of an equilmolar PAI-1/vitronectin 
mixture using SEDFIT. Equilmolar amounts of PAI-1 and vitronectin were mixed 
for 1 h and were analyzed by SV at 50,000 rpm at 25 °C.  This figure shows a 
representative data set collected using interference optics for an 8 µM PAI-
1/vitronectin mixture.  Data was analyzed using SEDFIT and the fitted data is given 
by the solid lines, with residuals for the fit shown below the data.  Scans are shown in 
different colors for clarity.  This type of analysis was carried out on varying 
equilmolar mixtures of PAI-1 and vitronectin, results for which are given in Fig. 4-3
and Table 4-II.
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Fig. 4-3. c(s) distribution analysis of equimolar mixtures of PAI-1 and 
vitronectin. Equilmolar amounts of PAI-1 and vitronectin were mixed for 1 h and 
were analyzed by SV at 50,000 rpm at 25 °C using SEDFIT.  Resulting c(s) 
distributions for a dilutions series originating from an 8 µM PAI-1/vitronectin 
mixture are shown in panels A (8µM mixture), B (3.2 µM mixture), and C (1.6 µM 
mixture).  A range of s values from 5 to 25 S is plotted for each mixture and two 
ranges are identified in the top panel by the red (5.1-7.4 S; intermediate complexes) 
and blue (7.5-25 S; higher order complexes) bars.  Species with s values less that 5 S 
are not shown here but are quantified in Table 4-II.
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Samples Protein Concentrations
Unbound 
Proteins 
(Fraction in s-
range from 1-
5 S ), %b
Intermediate 
Complexes 
(Fraction in s-
range from 5.1-
7.4 S ), %b
Higher-Order 
Complexes 
(Fraction in s-
range from 7.5-
25 S ), %b
Vitronectin + 
wt PAI-1
8 µM Vitronectin      
8 µM PAI-1c
26 24 50
Vitronectin + 
wt PAI-1
3.2 µM Vitronectin   
3.2 µM PAI-1c
25 45 30
Vitronectin + 
wt PAI-1
1.6 µM Vitronectin   
1.6 µM PAI-1c
30 64 6
Table 4-II:  Assembly of PAI-1 and vitronectin into intermediate and higher-order 
complexes.a
aRanges in s -values were defined for integration according to criteria outlined in 
Table 4-I, with species sedimenting with s -values in the range from 1-5 S 
representing free proteins, species with s -values in the range from 5.1-7.4 S 
representing intermediate 1:1 and 2:1 (PAI-1:vitronectin) complexes, and species 
sedimenting with s-values greater than 7.5 S representing higher-order complexes.
bSedimentation data were evaluated as c(s) profiles, and data were integrated using 
SEDFIT to determine the relative amounts of various PAI-1/vitronectin complexes 
formed.  Values were normalized by dividing the integrated values by the total 
loading signal in fringes, and multiplying by 100 to obtain a percentage of the 
various species formed.  Errors are ± 5%.
cC(s ) distributions of complexes with s-values >5 S for the three concentrations of 
vitronectin and wild-type PAI-1 samples are shown in Figure 4-3, panels  B-D.  
Free proteins that sediment in the 1-5 S range are not shown in the figure, but the 
integrations over this s -range are shown here.
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 coefficients above 5 S, is shown in Figure 4-3.  For each of the protein concentrations 
tested, the proportion of signal corresponding to s-values between 1-5 S, representing free 
PAI-1 and/or vitronectin, consistently was ~30 % of the total signal (not shown), consistent 
with our prior sedimentation equilibrium studies on 1:1 mixtures of the two proteins [127].  
The 5.1 - 7.4 S and 7.5 - 25 S integration ranges, corresponding to intermediate and 
higher-order complexes, respectively, are indicated by colored bars above Figure 4-3 
panel A.  What is most significant about the findings is the apparent reversibility of 
formation of higher-order complexes with s-values between 7.5-25 S, with a concomitant 
emergence of intermediate complexes in the 5.1-7.4 S range.  As demonstrated in Figure 4-
3 panel C with an equimolar concentration of PAI-1 and vitronectin at 1.6 µM, only 6 % of 
the total reaction mixture is present in the higher-order complexes with s-values above 7.5 S.  
This contrasts with the mixtures containing the 8 µM and 3.2 µM concentrations, which 
showed complexes in this range equal to 50 % and 30% of the total mass, respectively (Table 
4-II). 
 The decrease in the abundance of sedimenting species with s-values greater than 7.5 S in the 
more diluted mixtures is mirrored by the accumulation of intermediate species at ~6 S. For 
example, in the 1.6 µM equimolar mixture, with only 6% of the total mass sedimenting as 
higher-order species, a full 64 % of the total mass loaded corresponds to species in the 
intermediate s-range of 5.1-7.4 S.  A similar distribution of species was observed when 
the mixture of PAI1/vitronectin was further diluted to ~400 nM, approaching the detection 
limit of the analytical ultracentrifuge.  When comparing the samples measured at the 
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 highest concentration to more dilute samples, peaks in the c(s) distribution at intermediate 
sedimentation values from 5.1-7.4 S vary in peak width and position.  For example, the 
species observed at ~6.5 S in the 8 uM equimolar mixture shifts to a broader peak with a 
maximum near ~6 S at lower protein concentrations tested.  As discussed below, this 
sedimentation coefficient of ~6 S represents a mixture of 1:1 and 2:1 PAI-1/vitronectin 
complexes that are not resolved in this experiment.  Because of the apparent interdependence of 
species with intermediate (5.1 to 7.4 S) and high (7.5 to 25 S) sedimentation coefficients, we 
focused on characterizing the composition of the intermediate species in further 
experiments. 
  
 Formation of Higher-Order Complexes Occurs in a Concentration-Dependent 
Fashion—To test the concentration dependence of the assembly of oligomeric 
complexes, SV analysis was performed on mixtures where one of the proteins was held 
constant while the other was varied.  For one set of experiments (Figure 4-4, panel A), 
vitronectin was maintained at a constant concentration of 1.6 µM.  This particular 
vitronectin concentration leads to the assembly of a predominant species in the 
intermediate range with a sedimentation coefficient near 6 S (Figure 4-3).  Furthermore, 
this concentration is physiologically relevant and reflects the levels of vitronectin found 
in normal circulation [88,89,181].  As shown in Figure 4-4, panel A, increases in the 
molar concentration of PAI-1 relative to vitronectin alter the c(s) distributions, with 
several higher-order complexes that form at high concentrations of PAI-1.   
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Fig. 4-4. SV analysis to evaluate the concentration dependence of formation of 
higher-order PAI-1/vitronectin complexes. PAI-1 and vitronectin were mixed 
under conditions where the concentration of one protein was held constant while the 
other was varied.  The proteins were mixed for 1 h and were analyzed by SV at 
50,000 rpm at 20 °C with detection by interference optics.  Data were analyzed using 
SEDFIT.  Panels A and B show c(s) distributions for mixtures of 1.6 µM vitronectin
with 0.4 µM PAI-1 (black line), 1.6 µM PAI-1 (blue line), and 5.6 µM PAI-1 (red 
line).  Panel B gives an expanded view of the c(s) distribution between s values of 
4.5-15 S.  An asterisk denotes the critical 6.5 S complex.  Panel C shows the 
converse titration in which PAI-1 was held constant at 3.5 µM and the vitronectin
concentration was varied between 0.87 µM (black line), 1.7 µM (blue line), and 7 µM 
(red line).
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  A clearer picture of this dose-dependence is seen in Figure 4-4 panel B, which focuses 
more closely on species distributed between 4.5-15 S.  A sub-stoichiometric molar ratio 
of PAI-1 to vitronectin (1:4) results in the assembly of complexes primarily distributed 
between ~5 and 7 S.  When PAI-1 is mixed with vitronectin at equimolar levels, a 
significant increase in complexes in this range is evident.  Moreover, the partial 
resolution of the broad peak between 5-7 S into a peak at ~5.5 S and a shoulder at 6.5 S is 
noteworthy.  These species appear to represent PAI-1/vitronectin complexes with molar 
stoichiometries of 1:1 and 2:1, respectively (Table 4-I and see next section).  Also, some 
higher-order species with s-values greater than 7 S emerge in this mixture.  A further 
increase in PAI-1 concentration to a molar ratio of 4:1 results in further re-distribution of 
sedimenting species that is quite dramatic.  First, the broad peak becomes more resolved 
with a predominant peak at ~6.5 S, and a corresponding decrease in the ~5.5 S complex.  
Thus, the 2:1 PAI-1/vitronectin complex is favored at higher PAI-1 concentrations.  
Secondly, at this point there is an accumulation of significant levels of higher-order 
species with s-values greater than 7 S.  Multiple higher-order complexes are present, 
including those at s-values of 8.7 S, 12.9 S, 16.4 S, 20.7 S, and greater.  Thus, it appears 
that appreciable formation of these higher-order complexes is only seen when the 
intermediate 6.5 S complex is populated.   
 An experiment also was performed in which the PAI-1concentration was fixed and 
vitronectin was varied.  As shown in Figure 4-4 panel C, accumulation of PAI-
1/vitronectin complexes depends on the relative abundance of the two proteins.  The 
results of this experiment are similar to those in Figure 4-4 panel A, in which higher 
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 protein concentrations lead to the population of a 6.5 S complex and a concomitant 
generation of higher-order complexes.  Although the formation of higher-order 
complexes at the highest protein concentrations is apparent, the abundance of these 
complexes relative to total protein is less than observed at the highest protein 
concentrations measured in Figure 4-4 panel A.  This is an expected result since the 
highest protein concentrations in Figure 4-4 panel C correspond to excess vitronectin, i.e. 
experimental conditions that favor primarily the occupation of the high-affinity PAI-1-
binding site rather than the second, lower-affinity site on vitronectin.  As a result, there is 
less accumulation of the 6.5 S (2:1) intermediate and pursuant higher-order species, 
compared to the highest protein concentrations in Figure 4-4 panel A in which PAI-1 is in 
excess and both binding sites on vitronectin are occupied.  The analyses of varying 
protein ratios in Figure 4-4  support a mechanism for the accumulation of higher-order 
species (>7.5 S) via formation of the 6.5 S species as an intermediate.    
 
 Multi-Signal Sedimentation Velocity Analysis Confirms the Binding of Two PAI-1 
Molecules to Vitronectin—What is this critical complex that sediments with an s-value 
of 6.5 S?  Our hypothesis is that it is a 2:1 complex with 2 molecules of PAI-1 bound to 
distinct sites on a single molecule of vitronectin (Table 4-I).  We suggest that these two 
sites on vitronectin differ in affinity, with the high affinity site (Kd ~ 1 – 10 nM [23,27]) 
resident in the SMB domain and a second lower affinity site (Kd ~ 25-50 nM (Chapter 2 
[128] and Schar, C. S., and Peterson, C. B., unpublished data) located outside the SMB 
region at a yet unidentified locus.  Because of the differences in affinity, these binding 
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 sites should be occupied in a concentration-dependent fashion, and our SV results support 
this notion.  Furthermore, we hypothesize that it is the saturation of both binding sites 
that forms the crucial 2:1 complex that then serves as a physiological “trigger” to induce 
the formation of higher-order PAI-1/vitronectin complexes.  To test this hypothesis, a 
definitive identification of the composition and stoichiometry of this 6.5 S complex is 
needed.   
 For this purpose, we have used a new multi-wavelength approach that allows 
simultaneous analysis of each protein in the complex [177].  We have performed a global 
analysis of multi-signal SV data for unraveling the populations and stoichiometries of 
heterogeneous protein complexes formed between PAI-1 and vitronectin.  We have 
focused our attention primarily on the species identified at ~6.5 S.  Multi-wavelength 
analysis has been used fruitfully with this system of interacting proteins in our prior 
sedimentation equilibrium measurements [127], taking advantage of different absorbance 
properties for proteins selectively labeled with chromophores.  In a similar strategy, the 
SV analysis was carried out using labeled PAI-1 and/or labeled vitronectin by collecting 
absorption and interference optical data from the same cell. 
 Both PAI-1 and vitronectin were individually labeled with fluorescein for separate 
experiments.  For our initial analysis, c(s) distributions were calculated using SEDFIT.  
The resultant peaks were integrated, and the equivalent loading signals of the 
corresponding species were compared.  The results of this approach are shown in Figure 
4-5, showing c(s) distributions calculated from an SV experiment monitoring a mixture 
of FITC-vitronectin and unlabeled PAI-1.  From interference data, the resolution of the 
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Fig. 4-5. Multisignal analysis of complex formation between fluorescently-
labeled vitronectin and PAI-1 using SEDFIT. PAI-1 (8 µM) and fluorescein-
labeled vitronectin (2 µM) were mixed for 1 h and analyzed by SV at 50,000 rpm and 
20 °C.  Both interference and absorbance data were collected.  Absorbance was 
measured at 490 nm to monitor the sedimentation of fluorescein-labeled vitronectin, 
whereas interference was  used to monitor both proteins.  As shown here, initial 
analysis was carried out by individually fitting both sets of optical and absorbance 
data using SEDFIT.  c(s) distribution profiles for interference (solid line) and 
absorbance (dashed line) data demonstrate the formation of a dominant species at ~6 
S.  Integration over an s range of 5.5-7 S (bracket) using both data profiles was 
carried out to estimate the molar amounts of PAI-1 and vitronectin.
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 5.5 S and 6.5 S species is apparent.  However, the absorbance data arising from the label 
on vitronectin is not resolved into two separate peaks in this analysis.  This lower 
resolution for the absorbance data compared to the interference data is a direct result of 
the data acquisition rate for the two different types of data, since individual interference 
scans are collected in ~10 sec, while each absorbance scan requires several minutes for 
acquisition.  An overlay of the two signals indicates that vitronectin is present in both the 
5.5 S and 6.5 S complexes, and the ratio of integrated signals should reflect the molar 
ratio of the species in the complexes formed.  This measurement in the range of 5.1-7 S 
showed that species with these sedimentation coefficients had an average molar ratio of 
PAI-1:vitronectin of 1.5:1, but calculation of stoichiometries of the separate 5.5 S and 6.5 
S species could not be achieved due to the resolution limits in the absorbance 
measurements.   
 Therefore, a method was developed to globally analyze the data using multiple signals 
measured simultaneous during the sedimentation experiment to discriminate the 
composition and stoichiometry of species within the 5.1 – 7S range.  The analysis was 
implemented in the program SEDPHAT, for which features are described in detail 
elsewhere [177].  From a global multi-signal analysis, the new method permits a direct 
calculation of the separate c(s) distributions of the different protein components, termed 
ck(s), based on the pre-determined contributions of each protein to all of the observed 
signals [177].  The analysis shown in Figure 4-6, was performed on data acquired using 
fluorescein-labeled vitronectin and unlabeled labeled PAI-1 (Figure 4-6  panels A and B, 
interference and absorbance data, respectively).  Both sets of data were globally fit by the 
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Fig. 4-6. Global multisignal analysis of a PAI-1/vitronectin mixture using  
SEDPHAT. Mixtures of PAI-1 (8 µM) and fluorescein-labeled vitronectin (2 µM) 
were incubated for 1 h and analyzed by SV at 50,000 rpm at 20 °C.  Both 
interference and absorbance scans were taken every 4 min in the analytical 
ultracentrifuge.  Resulting profiles were analyzed using a noval multisignal analysis 
feature implemented in the program SEDPHAT.  Prior experiments were carried out 
to determine the chromophroric and interference-coupled extinction coefficients, 
which were included in the analysis.  SV data, with fits to each data set, are shown 
for interference (panel A) and absorbance (at 494 nm, panel B) data.  Vertical green
lines in both panels represent the boundaries on data included in the global analysis.  
Resulting residuals for each analysis are given below each SV data set.  
Representative results for global analyses are shown in Figs 4-7 and 4-8.
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 multi-signal/wavelength analysis approach using experimentally determined values 
representing both chromophoric and interference-coupled extinction coefficients.  Analyses 
resulted in well-fit data for the experiments, with both local and global errors in the acceptable 
range, as shown in the residuals below the data.  Similar results were obtained from the 
analysis using the opposite labeling strategy with fluorescein-labeled PAI-1 and unlabeled 
vitronectin (data not shown).   
 The analysis of the mixture using fluorescein-labeled vitronectin and unlabeled PAI-1 shows 
both protein components in co-sedimenting peaks, as expected since they form 
complexes (Figure 4-7).  The relative amounts of signal indicate that the complex with a 
sedimentation coefficient of ~6.5 S contains a molar excess of PAI-1, and integration of 
the peak areas in this c(s) distribution shows that this 6.5 S complex contains a molar ratio of 
2:1 PAI-1/vitronectin.  The calculation of this molar ratio relies on the relative heights of 
the boundaries of the sedimenting components detected using the two signals from 
interference and absorbance optics.  Thus, the multi-wavelength approach explicitly 
identifies the 2:1 intermediate that is required for assembly to higher-order species.  Also, 
the higher-order species that exhibits a sedimentation coefficient of ~8S (Figure 4-7) 
contains the same molar stoichiometry of vitronectin and PAI-1, identifying this species as the 
4:2 complex (Table 4-I).  The same approach applied to other higher-order complexes was 
less definitive (mainly due to their limited abundance and small contribution in the visible 
absorbance signal) but clearly indicated the presence of molar excesses of PAI-1 in several 
cases (data not shown).  
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Fig. 4-7. Multisignal analysis demonstrates the formation of a 2:1 PAI-
1/vitronectin complex at 6.5 S. Representative multisignal analysis using 
SEDPHAT with the distribution of PAI-1 and vitronectin represented by red and blue
lines, respectively.
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  A detailed interpretation of the peak shapes from this multi-wavelength analysis is not 
possible currently, due to probable effects of the signal/noise ratio on the degree of 
regularization in the calculated curves, and the potential influence of slight mismatches in 
the meniscus position of the different data sets.  It should be noted that in theory the 
component ck(s) distributions of interacting species can not necessarily be expected to be 
in perfect register, due to the effects of finite reaction kinetics (J. Dam, C.A. Velikovsky, 
R.A. Mariuzza, C. Urbanke, P. Schuck, manuscript submitted), and the dispersion of 
composition in the reaction boundary predicted by Gilbert-Jenkins theory [182] which 
can apply to c(s) distributions (J. Dam and P. Schuck, manuscript submitted).   Despite 
these effects, the integral over the peaks of the reaction boundary reports the 
stoichiometry of the complexes. Thus, the multi-signal analysis provides conclusive 
evidence that PAI-1 and vitronectin interact to form a 2:1 complex that sediments at ~6.5 S, 
supporting our hypothesis that formation of a 2:1 PAI-1/vitronectin complex serves as a 
building block in the formation of higher-order oligomers. 
 
 Oligomeric Forms of Vitronectin Persist at Long Incubation Times—PAI-1 is a 
unique member of the serpin family that spontaneously converts over time to a latent, 
non-inhibitory conformation [77,183].  This conformational change in PAI-1 also renders 
the protein incapable of binding to vitronectin [184].  To evaluate the effects of this 
transition to latent PAI-1 on the distributions of higher-order complexes, a time course 
was evaluated over > 24 hours.  In these experiments, equimolar mixtures of PAI-1 and 
vitronectin were incubated at room temperature for different time intervals and then 
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 subjected to SV analysis.  As shown in Figure 4-8, c(s) distributions for mixtures 
incubated at 1 hour and 6 hours are similar, with a near equivalent population of the 
species at ~6.5 S.  However, there is a redistribution of higher-order species with s-values 
greater than 7.5 S, most apparent for the species with a sedimentation coefficient ~8 S 
(Table 4-I).  It is probable that this redistribution reflects an accumulation of higher-order 
forms that assemble on a longer time scale than the 2:1 intermediate at ~6.5 S. 
 As incubation times are increased to 12 and 24 hours, there is further re-distribution, 
with a time-dependent loss of higher-order species.  These changes are attributed to 
dissociation of the complexes as PAI-1 is converted to the latent form that does not bind 
to vitronectin [184].  Consistently, the time-dependent loss of higher-order species 
correlates well with the rate at which PAI-1 converts to a latent form under these 
conditions [163].  Also consistent is the loss over time of the ~6.5 S (2:1) intermediate, 
coincident with the accumulation of significant amounts of free vitronectin and latent 
PAI-1.  In agreement with work described in Chapter 2 [119,128], some oligomeric 
forms of vitronectin persist, even at the longest times that correlate with complete loss of 
active PAI-1.  Indeed, almost 44 % of the total loading signal for vitronectin was still 
present as oligomers after 24 hours. 
 
 Salt Effects Demonstrate the Potential Role of Ionic Interactions In the Formation of 
a Vitronectin/PAI-1 Complex—Mixtures of vitronectin and PAI-1 were made in the 
presence of increasing concentrations of sodium chloride and tested for complex 
assembly using sedimentation velocity.  Results shown in Figure 4-9 demonstrate the 
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Fig. 4-8. Test for the formation of vitronectin oligomers as a function of time..
PAI-1 and vitronectin were mixed at equimolar concentrations of 3.3 µM and 
incubated at room temperature for various amounts of time and then analyzed by SV 
at 50,000 rpm at 25 °C using interference optics.  c(s) distributions at 1 h (blue line), 
6 h (red line), 12 h (green line), and 24 h (black line) time points are shown.
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Fig. 4-9. Test for the effects of NaCl concentration on the formation of PAI-
1/vitronectin complexes. Equimolar mixtures of vitronectin and PAI-1 were 
incubated at room temperature in PBS containing various amounts of NaCl: 150 mM
(black line), 250 mM (blue line), and 500 mM (red line) NaCl concentration.
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 reversibility of the 6.5 S vitronectin/PAI-1 complex to a slower-sedimenting species of 
~5.5 S at a salt concentration of 500 mM NaCl.  From these results, we speculate that the 
5.5 S and 6.5 S species observed here represent complexes of 1:1 and 1:2 
(vitronectin:PAI-1) stoichiometries, respectively, and that the salt effects demonstrate the 
importance of ionic interactions in maintaining a 1:2 molar ratio.   
     
 Assembly of PAI-1/Vitronectin Complexes is Independent of the Anti-Protease 
Activity of the Inhibitor—Is the spontaneous conversion of PAI-1 to a latent 
conformation required for accumulation of vitronectin oligomers that persist at long 
times, as shown in Figure 4-8?  Must PAI-1 be active as a protease inhibitor to be 
effective in promoting the formation of higher-order complexes?  To address such 
questions, mutant forms of PAI-1 were used that exhibited either slower rates of 
conversion to the latent form [158,168] or impaired anti-protease activity [169].  Several 
forms of PAI-1 have been engineered by introduction of strategic mutations that disfavor 
conversion to a latent structure and thus allow PAI-1 to retain activity for a long period of 
time.   
 Analysis of a stable form of PAI-1, the W175F mutant [168], gave a common c(s) 
distribution pattern of PAI-1/vitronectin complexes induced by W175F versus wild-type 
PAI-1 (Figure 4-10), with the distribution of species in the 1-5 S, 5.1-7.4 S and >7.5 S 
ranges summarized in Table 4-III.  It is clear from the results on this “stable” mutant that 
the inherent rate of conversion to a latent form is not a critical feature that determines the 
ability of PAI-1 to form higher-order complexes with vitronectin.   
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Fig. 4-10. c(s) distribution analysis of equilmolar mixtures of mutant forms of 
PAI-1 and human vitronectin. Equilmolar amounts of wild-type PAI-1 (3.2 µM) or 
mutant PAI-1 (3.3 µM) and vitronectin were mixed for 1 h and were analyzed by SV 
at 50,000 rpm at 25 °C using SEDFIT.  Resulting c(s) distributions are shown in 
panels A-D for mixtures of vitronectin and wild-type PAI-1 (black lines), stable 
mutant 14-1B PAI-1 (green lines), stable mutant W175F PAI-1 (red lines), and non-
inhibitory PAI-1R (blue lines).  Panels B and D give expanded plots of distibutions
shown in Panels A and C, respectively, for s values between 8 and 22 S to focus in 
on higher-order complexes formed. 
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Samples Protein Concentrations
Unbound 
Proteins 
(Fraction in s-
range from 1-
5 S ), %b
Intermediate 
Complexes 
(Fraction in s-
range from 5.1-
7.4 S ), %b
Higher-Order 
Complexes 
(Fraction in s-
range from 7.5-
25 S ), %b
Vitronectin + 
wt PAI-1
3.2 µM Vitronectin   
3.2 µM PAI-1c
25 45 30
Vitronectin + 
Y175F PAI-1
3.3 µM Vitronectin   
3.3 µM PAI-1
25 34 41
Vitronectin + 
PAI-1R
3.3 µM Vitronectin   
3.3 µM PAI-1
20 40 40
Vitronectin + 
14-1B PAI-1
3.3 µM Vitronectin   
3.3 µM PAI-1
31 44 25
Table 4-III:  Assembly of complexes between different recombinant forms of PAI-1 
and vitronectin.a
aRanges in s -values were defined for integration according to criteria outlined in 
Table 4-I, with species sedimenting with s -values in the range from 1-5 S 
representing free proteins, species with s -values in the range from 5.1-7.4 S 
representing intermediate 1:1 and 2:1 (PAI-1:vitronectin) complexes, and species 
sedimenting with s-values greater than 7.5 S representing higher-order complexes.
bSedimentation data were evaluated as c(s) profiles, and data were integrated using 
SEDFIT to determine the relative amounts of various PAI-1/vitronectin complexes 
formed.  Values were normalized by dividing the integrated values by the total 
loading signal in fringes, and multiplying by 100 to obtain a percentage of the 
various species formed.  Errors are ± 5%.
cC(s ) distributions of complexes with s-values >5 S for the three concentrations of 
vitronectin and wild-type PAI-1 samples are shown in Figure 4-3, panels  B-D.  
Free proteins that sediment in the 1-5 S range are not shown in the figure, but the 
integrations over this s -range are shown here.
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  Another PAI-1 mutant tested in these experiments was the non-inhibitory mutant PAI-
1R [169].  This double arginine mutant (T333R and A335R) is impaired in its ability to 
act as an inhibitor of either tPA or uPA due to the introduction of charges into strategic 
positions in the reactive center loop that impede the insertion of this reactive center loop 
into the central β-sheet of the protein upon cleavage by plasminogen activators [169].  
However, this mutant PAI-1 retains the ability to bind vitronectin.  The structural changes 
result in PAI-1R acting as a substrate, not an inhibitor, for plasminogen activators; as 
such, this mutant serves as a valuable tool for studying a variety of non-proteolytic roles 
of PAI-1 that are important during processes like cell migration and tissue remodeling 
[135,138,185,186].  As summarized in Table 4-III, PAI-1R induces a similar formation of 
higher-order species as wild-type PAI-1.  These findings indicate that the ability of PAI-1 
to promote the formation of higher-order complexes with vitronectin is independent of its 
ability to inhibit plasminogen activators.     
 Because of potential experimental complications that may arise due to the inherent slow 
rate of conversion to latency by native PAI-1, many researchers have opted in their 
studies to use the stable variant of PAI-1 that has been best characterized [157,158]  This 
PAI-1 variant, denoted 14-1B, contains 4 mutations (Asn150His; Lys154Thr; Gln319Leu; 
Met354Ile) and is the form of PAI-1 that has been crystallized [160].  These mutations 
result in a delay in the transition of PAI-1 to latency by approximately 70-fold, with no 
reported change in inhibition of tPA or uPA.  Although many current structural and 
functional studies rely on the use of the stable 14-1B PAI-1, it appears that there are some 
distinctions between native PAI-1 and the stable conformer.  For example, uPA reacts 
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 differently with native PAI-1 and the 14-1B variant in the presence of the non-ionic 
detergent Triton X-100, with a reduction in the inhibitory activity against both forms 
[161].  Because of the possibility that there may be important structural and/or functional 
differences, the stable 14-1B variant was compared to native PAI-1 in the fibroblast 
binding assay. 
   
Discussion 
 Arguably, the most important physiological ligand of vitronectin is PAI-1.  Vitronectin 
stabilizes PAI-1 in its active conformation, and as an adhesive protein, serves to localize 
PAI-1 inhibition at specific sites of tissue damage.  PAI-1 binding to vitronectin results in 
profound conformational rearrangements, which subsequently result in the formation of 
multimeric structures with binding properties different from that of monomeric 
vitronectin [119,127].  Multimeric forms of vitronectin have been shown to readily 
associate with both cell surface receptors and ECM components [47,61,118,119,129-
132], indicating that multimerization in vivo might be the key step leading to the 
conversion of vitronectin to a matrix-associated form.  Importantly, both vitronectin and 
PAI-1 have been detected co-locally with tissues undergoing wound healing or tumor 
metastasis [102,111,123-126], suggesting that the two proteins serve as co-factors in 
matrix deposition and remodeling. 
 The mechanism through which vitronectin and PAI-1 assemble to form complexes that 
display adhesive properties at the cell-matrix interface is unknown.  Earlier reports from 
this lab and others demonstrated that vitronectin binding to PAI-1 leads to the occupation 
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 of two distinct PAI-1-binding sites on vitronectin, and this event leads to the building of 
higher-order complexes [119,127,128].  Sedimentation equilibrium studies using 
analytical ultracentrifugation to evaluate vitronectin/PAI-1 complexes demonstrated the 
formation of a large (~300 kDa) intermediate species consisting of 4 molecules of PAI-1 
bound to 2 molecules of vitronectin [127].  These higher forms of vitronectin/PAI-1 
complexes are adhesive in nature, and through multivalent interactions rapidly associate 
with cell surfaces and the ECM [123,128]. 
 The goal of this study was to add additional information regarding complex formation 
between vitronectin and PAI-1 to better understand the assembly process and identify the 
types of higher-order complexes that form.  Equilibrium studies evaluating the binding of 
vitronectin to the fluorescently-tagged NBD-S119C-PAI-1 resulted in sigmoidally-
shaped binding isotherms indicative of an allosteric event.  Data fits to the Hill equation 
indicated that allosteric binding between vitronectin and PAI-1 leads to the occupation of 
two PAI-1-binding sites.  This is in agreement with studies from this lab using 
sedimentation equilibrium and competition studies using site-specific monoclonal 
antibodies [127]. 
 Sedimentation velocity experiments provide valuable information regarding the step-
wise assembly of higher-order species that form when vitronectin interacts with PAI-1 
over time. These findings show a strong dependence on PAI-1 concentration on the sizes 
of vitronectin/PAI-1 complexes that form.  Some complexes were shown to be dependent 
on ionic strength, in particular a complex that most likely represents a 1:2 
vitronectin/PAI-1 species.  Time-course studies provide information regarding the 
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 reversibility and long-term survival of assembled complexes, especially those that remain 
even after PAI-1 has converted to the latent, non-vitronectin binding form.  Combining 
this information with our previous findings, we can develop a working model that helps 
describe the assembly process leading to the step-wise formation of higher-order 
vitronectin/PAI-1 complexes that are functionally important, Figure 4-11 shows the 
schematic of a working model describing the assembly of vitronectin/PAI-1 complexes. 
 In this model, PAI-1 first associates with a high-affinity binding site (SMB domain) on 
vitronectin and forms a 1:1 complex.  Binding of PAI-1 to the first site has an allosteric 
effect on a second PAI-1-binding site that results in the formation of a 1:2 
(vitronectin:PAI-1) stoichiometric complex.  Recent evidence from stopped-flow studies 
using fluorescence quenching demonstrates that the formation of the 1:2 complex, a slow 
PAI-1-independent step (first-order rate constant of 0.04 sec-1) that reflects a 
conformation change in vitronectin (manuscript in preparation).  This conformationally 
perturbed 1:2 vitronectin/PAI-1 complex is prone to self-association and serves as the 
building scaffold for higher-order complexes.  Throughout the assembly process, PAI-1 
is cycled on and off the complexes that form, and over time slowly exits the process 
following its conversion to latency.  At very long times, only stable vitronectin multimers 
remain, with a significant population returning to the monomeric form. 
 Future studies are required to help clarify and expand on the model presented in Figure 
4-11.  Very recent stopped-flow experiments performed by our collaborator Dr. Grant 
Blouse at Henry Ford Health Systems in Detroit define second-order rate constants of 2 x 
106 M-1sec-1 and 7.6 x 106 M-1sec-1 for the first two binding events that occur between 
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Fig. 4-11. Model for formation of multivalent complexes via the 6.5 S PAI-1/vitronectin intermediate. In 
this model, PAI-1 (blue circles with black, exposed loop) binds to vitronectin (red ovals) in a concentration-
dependent manner to form important intermediate 1:1 and 2:1 PAI-1/vitronectin complexes.  A conformational 
change producing “activated” vitronectin is indicated by the conversion of vitronectin to a structurally altered 
form (red stars).  Activation of vitronectin is coupled with oligomerization, leading to the assembly of the 4:2 
PAI-1/vitronectin complex and additional higher order species.  Over the course of time, there is slow release of 
latent PAI-1 (blue circle with white, buried loop) which is possibly released from any of the various 
intermediates formed and cannot associate with vitronectin.  Structural activation of vitronectin is also associated 
with the accumulation of stable higher-order vitronectin oligomers over time. 
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 vitronectin and PAI-1.  Both events are PAI-1-dependent and are followed by a 
conformational change in vitronectin, as discussed above, that leads down the path of 
higher-order assembly.  Additional techniques that are currently being used to address 
our assembly model include fluorescence anisotropy, fluorescence energy transfer 
(FRET), and CD spectroscopy. In addition, more sedimentation velocity experiments will 
be applied using mult-signal detection systems and global analysis to determine the molar 
stoichiometries of vitronectin/PAI-1 complexes in c(s) distributions to better characterize 
the types and sizes of higher-order species that form.  Structural studies like neutron 
scattering and high-resolution electron microscopy will aid in understanding the physical 
properties of higher-order complexes.  Finally, by combining information gained from 
the studies described above, especially those coming from analytical ultracentrifugation, 
stopped-flow kinetics, and fluorescence polarization, we can use computer  algorithms to 
simulate the assembly process of complex formation and be able to predict the effects of 
varying parameters, such as PAI-1 concentration.  As PAI-1 levels in circulation are 
much lower than we can use in our experimental approaches to obtain usable signals, we 
can instead predict the formation of vitronectin/PAI-1 complexes using simulations based 
on more physiological concentrations of PAI-1.  Studies like these are important when 
considering the potential dependence that processes like tumor growth and angiogenesis 
have on local PAI-1 concentrations [165,187]. 
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